Archive for June, 2010

CPI Aero (CVU) Awarded Follow-On Order for Wing Kits

EDGEWOOD, N.Y.–(BUSINESS WIRE)–CPI Aerostructures, Inc. (“CPI Aero®”) (NYSE Amex: CVU) announced today it has received a purchase order for Outer Wing Panel (OWP) kits for use in the manufacture of wings for the E-2D Advanced Hawkeye and the C-2A Greyhound aircraft from Northrop Grumman Corporation valued at up to $27.6 million. The purchase order includes firm, funded requirements valued at approximately $16.4 million and options valued at an additional $11.2 million. CPI Aero has received advanced funding authorization from Northrop Grumman for specific long lead-time activities.

CPI Aero received the initial order for E-2D OWP kits, valued at $7.9 million, in June 2008. This follow-on order increases the total value of funded orders received by CPI Aero for OWP kits to approximately $24.3 million. Including options, the order value of these kits is up to $35.5 million. The period of the contract, including options, is the second quarter of 2010 through the fourth quarter of 2013. The U.S. Navy’s program of record is for 75 E-2D Advanced Hawkeye aircraft. Potential program value to CPI Aero is approximately $98 million over an 8-year period, ending June 2016. The E-2D and the C-2A share common Outer Wing Panels, increasing the potential overall contract value to CPI Aero approximately $110 million through 2016.

Edward J. Fred, CPI Aero’s President & CEO stated, “We are quite pleased that the initial E-2D Outer Wing Panel contract is increasing in scope to include the C-2A aircraft and that CPI Aero is now an integral supplier to Northrop Grumman, the original equipment manufacturer, for two of the Navy’s critical carrier-based platforms. As a Northrop Grumman ‘Supplier of the Year’ in both the ‘Structures’ and ‘Small Business’ categories, we take great pride in our relationship with Northrop Grumman and will continue to strive to make this a completely successful program.”

Fred continued, “With this award, CPI Aero’s total year-to-date award amount from all customers is $30.9 million, compared to $4.8 million for the same period last year and $23.4 million for all of 2009. Of this year’s total, $25.6 million represents subcontract awards for both military and commercial aircraft from major aerospace companies, compared to $2.1 million of subcontract awards for the same period last year.”

About Northrop Grumman Corporation

Northrop Grumman Corporation is a leading global security company whose 120,000 employees provide innovative systems, products, and solutions in aerospace, electronics, information systems, shipbuilding and technical services to government and commercial customers worldwide.

About CPI Aero

CPI Aero is engaged in the contract production of structural and other aircraft parts for leading prime defense contractors, the U.S. Air Force, and other branches of the armed forces. In conjunction with its assembly operations, CPI Aero provides engineering, technical and program management services. Among the key programs that CPI Aero supplies are the E-2D Hawkeye surveillance aircraft, the C-2A Greyhound cargo aircraft, the UH-60 BLACK HAWK helicopter, the S-92® helicopter, the MH-60S mine countermeasure helicopter, the Gulfstream G650, C-5A Galaxy cargo jet, the T-38 Talon jet trainer, the A-10 Thunderbolt attack jet, and the E-3 Sentry AWACS jet. CPI Aero is included in the Russell Microcap® Index.

The above statements include forward looking statements that involve risks and uncertainties, which are described from time to time in CPI Aero’s SEC reports, including CPI Aero’s Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended March 31, 2010.

CPI Aero® is a registered trademark of CPI Aerostructures, Inc.

Wednesday, June 30th, 2010 Uncategorized Comments Off on CPI Aero (CVU) Awarded Follow-On Order for Wing Kits

Plumas Bancorp (PLBC) Records a $1.4 Million Gain Resulting From Its New Merchant Processing Alliance

QUINCY, CA–(Marketwire – 06/30/10) – Plumas Bancorp, (NASDAQ:PLBCNews), a bank holding company and the parent company of Plumas Bank, announced that it has entered into an alliance with a world-wide merchant processing leader. As a result of the sale of its merchant processing business, Plumas Bancorp expects to record a one-time gain of $1.4 million in the second quarter.

Andrew J. Ryback, Plumas Bank’s interim president and chief executive officer, commented, “This alliance allows us to focus on our customers’ core banking needs while providing them with a superior merchant processing solution.”

About Plumas Bank:

Founded in 1980, Plumas Bank is a locally owned and managed full-service community bank based in Northeastern California. The Bank operates eleven branches located in the counties of Plumas, Lassen, Placer, Nevada, Modoc and Shasta. Plumas Bank offers a wide range of financial and investment services to consumers and businesses and has received nationwide Preferred Lender status with the U. S. Small Business Administration. For more information on Plumas Bancorp and Plumas Bank, please visit www.plumasbank.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

Forward-looking statements in this Press Release are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the frequency and magnitude of foreclosure of the Company’s loans; the effects of the Company’s lack of a diversified loan portfolio, including the risks of geographic and industry concentrations; the accuracy of the Company’s financial statement estimates and assumptions, including the estimate for the Company’s loan loss provision; the Company’s ability to integrate acquisitions; the strength of the U.S. economy and the local economies where the Company conducts operations; harsh weather conditions; fluctuations in inflation, interest rates, or monetary policies; changes in the stock market and other capital and real estate markets; legislative or regulatory changes; customer acceptance of third-party products and services; increased competition and its effect on pricing; technological changes; the effects of security breaches and computer viruses that may affect the Company’s computer systems; changes in consumer spending and savings habits; the Company’s growth and profitability; changes in accounting; and the Company’s ability to manage the risks involved in the foregoing. Additional factors can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and the Company’s other filings with the SEC, which are available at the SEC’s internet site (www.sec.gov). Forward-looking statements in this Press Release speak only as of the date of the Press Release, and the Company assumes no obligation to update forward-looking statements or the reasons why actual results could differ.

Wednesday, June 30th, 2010 Uncategorized Comments Off on Plumas Bancorp (PLBC) Records a $1.4 Million Gain Resulting From Its New Merchant Processing Alliance

Tesla (TSLA) Announces Pricing of Initial Public Offering

Jun. 30, 2010 (Business Wire) — Tesla Motors, Inc. (Nasdaq:TSLA), a manufacturer of highway-capable fully electric vehicles and electric vehicle powertrain components, today announced its initial public offering of 13,300,000 shares of its common stock at a price to the public of $17.00 per share. The shares will begin trading on Tuesday, June 29, 2010 on the NASDAQ Global Select Market under the ticker symbol “TSLA.” Of the shares in the offering, 11,880,600 shares are being offered by the company and 1,419,400 shares are being offered by selling stockholders. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional aggregate of 1,995,000 shares of common stock to cover over-allotments, if any. Tesla will not receive any proceeds from the sale of shares by the selling stockholders.

Goldman, Sachs & Co., Morgan Stanley, J.P. Morgan and Deutsche Bank Securities are acting as the joint book-running managers for the offering.

The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., via telephone: (866) 471-2526; facsimile: (212) 902-9316; email: prospectus-ny@ny.email.gs.com; or standard mail at Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282-2198; from Morgan Stanley & Co. Incorporated, via telephone: (866) 718-1649; email: prospectus@morganstanley.com; or standard mail at Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, New York, NY 10014; from J.P. Morgan Securities Inc., via telephone: (718) 242-8002; or standard mail at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; or from Deutsche Bank Securities Inc., via telephone: (800) 503-4611; or standard mail at 100 Plaza One, Jersey City, NJ 07311 Attn: Prospectus Department.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tesla Motors, Inc.

Tesla designs, develops, manufactures and sells high-performance fully electric vehicles and advanced electric vehicle powertrain components. In addition to designing and manufacturing vehicles, Tesla sells and services them through its own sales and service network. Tesla has delivered over 1,000 Tesla Roadsters to customers in 22 countries. Tesla is headquartered in Palo Alto, California.

Wednesday, June 30th, 2010 Uncategorized Comments Off on Tesla (TSLA) Announces Pricing of Initial Public Offering

Celgene (CELG) to Acquire Abraxis BioScience Inc. (ABII)

Jun. 30, 2010 (Business Wire) — Celgene Corporation (NASDAQ: CELG) and Abraxis BioScience Inc. (Nasdaq: ABII) today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock. The upfront payment values Abraxis BioScience at approximately $2.9 billion, net of cash. Each share will also receive one tradeable Contingent Value Right (CVR), which entitles its holder to receive payments for future regulatory milestones and commercial royalties. The transaction is expected to be modestly dilutive to non-GAAP earnings in 2011 and accretive in 2012 and beyond.

The acquisition of Abraxis BioScience accelerates Celgene’s strategy to become a global leader in oncology. The transaction adds ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) to the Company’s existing portfolio of leading cancer products. ABRAXANE was approved in January 2005 by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ABRAXANE was approved by the European Medicines Agency in January 2008 for a similar indication. Additionally, ABRAXANE® has received orphan drug designation for stage IIB-IV melanoma and pancreatic cancer.

“The acquisition of Abraxis BioScience is an exceptional strategic fit that will accelerate our strategy of becoming a global leader in oncology,” said Bob Hugin, Chief Executive Officer of Celgene Corporation. “We are excited by the opportunity to leverage our clinical, regulatory and commercial capabilities to provide metastatic breast cancer patients with an innovative treatment in ABRAXANE. We are also excited by the potential of ABRAXANE to treat additional solid tumor malignancies such as non-small cell lung and pancreatic cancer. Finally, the potential of nab®-based therapeutics developed by Abraxis coupled with Celgene’s innovative science offers the potential to deliver long-term value to patients, doctors and all of our stakeholders.”

“Our nab technology platform is changing the treatment paradigm for difficult-to-treat cancers,” said Patrick Soon-Shiong, M.D., Executive Chairman of Abraxis BioScience. “In Celgene we have found the ideal partner to further expand the reach of ABRAXANE and our other treatments, in order to improve the lives of patients worldwide.”

About nab®-Driven Chemotherapy

Abraxis BioScience has developed a proprietary nanoparticle albumin bound (nab) technology which leverages albumin nanoparticles for the active and targeted delivery of chemotherapeutics to the tumor. This nab-driven chemotherapy provides a new paradigm for penetrating the blood-stroma barrier to reach the tumor cell. The proposed mechanism of delivery of this nab-driven chemotherapy is thought to be by targeting a previously unrecognized tumor-activated, albumin-specific biologic pathway with a nanoshell of the human blood protein albumin. This nano-shuttle system is believed to activate an albumin-specific (Gp60) receptor-mediated transcytosis path through the cell wall of proliferating tumor cells, using caveolin-1 activated caveolar transport. Once in the stromal micro-environment, the albumin-bound drug may be preferentially localized by a second albumin-specific binding protein, SPARC, a protein secreted into the stroma by tumor cells. The resulting collapse of stroma surrounding the tumor cell may thus enhance the delivery of the nab-chemotherapeutic to the intracellular core of the tumor cell itself.

Recent ABRAXANE Clinical Data: First-line Non-small Cell Lung Cancer

At the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held earlier this month in Chicago, 34 scientific abstracts evaluating the use of ABRAXANE were presented. Data presented from a randomized phase III trial evaluating ABRAXANE plus carboplatin showed a statistically significant (p=0.005) 31 percent improvement in overall response rate (ORR) when compared with paclitaxel plus carboplatin in the first-line treatment of patients with non-small cell lung cancer (NSCLC). These data achieved the primary end point agreed to with the FDA in a Special Protocol Assessment. In addition, a retrospective analysis of the highly difficult-to-treat subset of squamous cell carcinoma, showed a 67 percent improvement in ORR (p<0.001) in those who received the ABRAXANE combination versus those who received the paclitaxel combination.

Recent ABRAXANE Clinical Data: Advanced Pancreatic Cancer

Data was also presented at the recent ASCO meeting from a phase II clinical study evaluating ABRAXANE in advanced pancreatic cancer patients who have progressed on gemcitabine-based therapy. Treatment resulted in 58 percent of patients achieving six-month overall survival (OS), with a median survival of 7.3 months and a median progression-free survival (PFS) of 1.6 months. Five patients remain alive at a median follow-up of 12.7 months, including one patient with stable disease (SD) on cycle 15 of therapy. These results follow data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) in April 2010 from a phase 1/2 study of ABRAXANE in combination with gemcitabine, which demonstrated increased survival in first-line treatment of patients with advanced pancreatic cancer. Median OS for 44 patients treated at the recommended dose of 125 mg/m2 nab-paclitaxel (ABRAXANE) plus gemcitabine (1000 mg/m2) was 12.2 months, a doubling of survival compared to historical control of gemcitabine alone. Enrollment is ongoing for a phase III trial program evaluating nab-paclitaxel plus gemcitabine versus gemcitabine alone as a first-line therapy for advanced metastatic pancreatic cancer.

Terms of the Agreement

The transaction has been approved by the Board of Directors of both companies and is subject to customary closing conditions, including the approval of the acquisition by stockholders of Abraxis Bioscience and the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock. The upfront payment values Abraxis BioScience at approximately $2.9 billion, net of cash. Each share will also receive one tradeable CVR, which will entitle its holder to receive a pro rata share of the following payments:

  • $250 million cash payment upon certain U.S. approval of ABRAXANE® by FDA for NSCLC with progression-free survival claim in U.S. label
  • $300 million in cash upon the approval of ABRAXANE by FDA for pancreatic cancer with overall survival claim in U.S. label.
  • $100 million cash payment upon FDA approval of ABRAXANE for pancreatic cancer by April 1, 2013.
  • Potential cash royalty payments upon achievement of certain ABRAXANE and nab-pipeline products net revenue thresholds.

The acquisition of Abraxis BioScience is expected to close in the fourth quarter of 2010.

Morgan Stanley & Co. Incorporated is acting as financial advisor to Celgene on the transaction. Lazard Freres & Co., Goldman Sachs & Co., and BofA Merrill Lynch are acting as co-financial advisors to Abraxis BioScience. Legal counsel for Celgene is Jones Day and Proskauer Rose LLP, and Abraxis BioScience’s legal counsel is Fried, Frank, Harris, Shriver & Jacobson LLP.

About ABRAXANE®

ABRAXANE is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience’s proprietary nab® technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin, a naturally-occurring human protein. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel. ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric.

The U.S. Food and Drug Administration approved ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. For the full prescribing information for ABRAXANE please visit http://www.abraxane.com.

About Abraxis BioScience, Inc.

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s portfolio includes chemotherapeutic compound (ABRAXANE), which is based on the company’s proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 39 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit http://www.abraxisbio.com.

Conference Call and Webcast Information

Celgene will host a conference call to discuss the strategic acquisition of Abraxis BioScience on June 30, 2010, at 9 a.m. ET. The conference call and accompanying slides will be available by webcast at www.celgene.com. An audio replay of the call will be available from noon ET June 30, 2010, until midnight ET July 7, 2010. To access the replay, in the U.S. dial 800-642-1687; outside the U.S. dial 706-645-9291; and enter reservation number 84971562

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company’s Web site at www.celgene.com.

Additional Information about the Transaction and Where to Find It

This press release shall not constitute an offer of any securities for sale. The acquisition will be submitted to Abraxis Bioscience’s stockholders for their consideration. In connection with the acquisition, Celgene and Abraxis Bioscience intend to file relevant materials with the Securities and Exchange Commission (SEC), including a registration statement, a proxy statement/prospectus and other relevant documents concerning the merger. Investors and stockholders of Celgene and Abraxis Bioscience are urged to read the registration statement, the proxy statement/prospectus and other relevant documents filed with the SEC when they become available, as well as any amendments or supplements to the documents because they will contain important information about Celgene, Abraxis Bioscience and the merger.

Stockholders of Celgene and Abraxis Bioscience can obtain more information about the proposed transaction by reviewing the Form 8-K to be filed by Celgene and Abraxis Bioscience in connection with the announcement of the entry into the merger agreement, and any other relevant documents filed with the SEC when they become available. The registration statement, the proxy statement/prospectus and any other relevant materials (when they become available), and any other documents filed by Celgene and Abraxis Bioscience with the SEC, may be obtained free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by directing a written request to: Celgene Corporation, 86 Morris Avenue, Summit, New Jersey, 07901, Attention: Investor Relations, or Abraxis Bioscience Inc., 11755 Wilshire Blvd., Los Angeles, CA, 90025, Attention: Investor Relations. Investors and stockholders are urged to read the registration statement, the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the merger.

Participants in Solicitations

Celgene, Abraxis Bioscience and their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies from stockholders of Abraxis Bioscience in connection with the merger. Information regarding Celgene’s directors and officers is available in Celgene’s proxy statement on Schedule 14A for its 2010 annual meeting of stockholders, which was filed with the SEC on April 30, 2010. Information regarding Abraxis Bioscience’s directors and executive officers is available in Abraxis Bioscience’s proxy statement on Schedule 14A for its 2009 annual meeting of stockholders, which was filed with the SEC on October 30, 2009. Additional information regarding the interests of such potential participants will be included in the proxy statement and the other relevant documents filed with the SEC when they become available.

Forward-Looking Statements

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under Celgene’s control. The Company’s actual results, performance, or achievements could be materially different from those projected by these forward-looking statements. The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements include the risk that the acquisition of Abraxis Bioscience may not be consummated for reasons including that the conditions precedent to the completion of the acquisition may not be satisfied; the possibility that the expected benefits from the proposed merger will not be realized, or will not be realized within the anticipated time period; the risk that Celgene’s and Abraxis Bioscience’s businesses will not be integrated successfully; the possibility of disruption from the merger making it more difficult to maintain business and operational relationships; any actions taken by either of the companies, including but not limited to, restructuring or strategic initiatives (including capital investments or asset acquisitions or dispositions); and other risks that are discussed in Celgene’s filings with the SEC, such as Celgene’s Form 10-K, 10-Q and 8-K reports and in Abraxis Bioscience’s filings with the SEC, such as its Form 10-K, 10-Q and 8-K reports. Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.

Wednesday, June 30th, 2010 Uncategorized Comments Off on Celgene (CELG) to Acquire Abraxis BioScience Inc. (ABII)

Argon ST (STST) Announces Agreement to be Acquired by The Boeing Company (BA)

Jun. 30, 2010 (Business Wire) — Argon ST [NASDAQ: STST] and The Boeing Company [NYSE: BA] today announced that they have entered into an agreement for Boeing’s acquisition of Argon ST in an all cash tender offer and merger for $34.50 per share, or approximately $775 million, net of cash acquired.

The agreement to acquire Argon ST, a leading developer of command, control, communications, computers, combat systems, intelligence, surveillance, and reconnaissance (C5ISR), advances Boeing’s growth strategy and expands its capabilities to address the C5ISR, cyber and intelligence markets.

“We’re very pleased to join The Boeing Company,” said Dr. Terry Collins, chairman and chief executive officer of Argon ST. “Our employee teams know each other well, and we are excited to now continue our combined support to our warfighters and first responders as one company.”

Once acquired, Argon ST will be a stand-alone subsidiary of Boeing and a new division of Boeing Network & Space Systems, a business within the Boeing Defense, Space & Security operating unit. Argon ST will continue to be led by Collins and his management team, which will help ensure a seamless transition for employees and customers.

“Combining the strength of Boeing with the experience of Argon ST will significantly accelerate our capabilities in sensors, communications technologies and information management,” said Dennis Muilenburg, president and CEO of Boeing Defense, Space & Security. “Today’s announcement follows two years of partnering with Argon ST’s talented employees who, like Boeing employees, take pride in developing and deploying world-class engineering solutions for our customers.”

Founded in 1997 and headquartered in Fairfax, Virginia, Argon ST develops sensors and networks designed to exploit, analyze and deliver information for real-time situational awareness. In fiscal 2009, the company generated $366 million in revenues. Argon ST has operating locations in Virginia, California, Michigan, Pennsylvania, Florida, Maryland and Texas, and has approximately 1,000 employees.

“Joining Boeing will have a very positive impact on our combined C5ISR offerings,” stated Kerry Rowe, president and chief operating officer of Argon ST. “We look forward to an even stronger position in the marketplace both domestically and internationally, utilizing Boeing’s global footprint and strong customer relationships.”

The completion of the transaction is subject to a majority of the outstanding Argon ST shares being tendered, as well as satisfactory completion of other customary closing conditions, including U.S. regulatory approval.

The definitive agreement was unanimously approved by Argon ST’s Board of Directors, and Argon ST’s Board intends to recommend that the company’s stockholders tender their shares in the offer.

Boeing plans to fund the transaction with existing cash and expects to close by the end of September 2010.

Argon ST’s exclusive financial advisor on the transaction was Stone Key Partners LLC and its legal advisor was DLA Piper LLP (US).

About Argon ST, Inc.

Argon ST, Inc. designs, develops, and produces systems and sensors for the Command, Control, Communications, Computers, Combat Systems, Intelligence, Surveillance, and Reconnaissance (C5ISR) markets including SIGINT (Signals Intelligence), ESM (Electronic Support Measures), EW (Electronic Warfare), IO (Information Operations), imaging, and acoustic systems serving domestic and international markets.

Important Information about the Tender Offer

The tender offer described herein has not yet commenced, and this press release is neither an tender offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Boeing will cause its subsidiary, Vortex Merger Sub, Inc. to file a tender offer statement on Schedule TO with the SEC. Investors and Argon stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by Argon with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov. A copy of the tender offer statement and the solicitation/recommendation statement will be made available free of charge to all stockholders of Argon ST, Inc. at www.argonst.com or by contacting Argon ST, Inc. at 12701 Fair Lakes Circle, Suite 800, Fairfax, Virginia 22033, (703) 322-0881.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words “future”; “anticipate”; “potential”; “believe”; or similar statements are forward-looking statements. Risks and uncertainties include uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of the Argon stockholders will tender their stock in the offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, business partners or governmental entities; as well as risks detailed from time to time in Argon’s public disclosure filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2009, subsequent quarterly filings on Form 10-Q and the solicitation/recommendation statement to be filed in connection with the tender offer. The information contained herein is as of June 30, 2010. Argon disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release or otherwise. Copies of Argon’s public disclosure filings are available from its investor relations department.

Wednesday, June 30th, 2010 Uncategorized Comments Off on Argon ST (STST) Announces Agreement to be Acquired by The Boeing Company (BA)

PROLOR Biotech (PBTH) Granted EU GMP Certification for Lead Candidate hGH-CTP

NES-ZIONA, Israel, June 29 /PRNewswire-FirstCall/ — PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has received formal Good Manufacturing Practice (GMP) certification for hGH-CTP, the company’s proprietary biobetter version of human growth hormone.  GMP certification is required by the European Union (EU) clinical trials legislation as a precondition for conducting clinical trials in EU member countries.

Article 13 of 2001/20/EC of the EU clinical trials legislation was established to ensure, prior to the initiation of a clinical trial study in any EU member country, that the drug product to be used in such clinical trial study has been manufactured in accordance with EU GMP regulations and meets the conditions of the clinical trial authorization and the product specification file.  PROLOR’s facilities for working with hGH-CTP, as well as those of the contract manufacturing organizations for the drug substance and drug product, were inspected and audited as part of the assessment process.

“EU GMP certification is a rigorous process that we are delighted to have completed successfully,” said Abraham Havron, Ph.D., CEO of PROLOR.  “Preparation for the manufacturing audit process and the audit itself were a top priority for the company and a critical milestone for the first half of 2010.  This certification allows PROLOR to move forward with our hGH-CTP Phase II clinical trial, which we expect to initiate later this summer.”

ABOUT hGH-CTP

hGH-CTP is PROLOR’s proprietary biobetter version of human growth hormone.  hGH is used for the long-term treatment of children and adults with growth hormone deficiency due to inadequate secretion of endogenous growth hormone.  It is also sometimes used to counter involuntary weight loss and certain physical manifestations of aging.  Currently available forms of hGH must be injected daily.  In contrast, hGH-CTP is expected to require only bi-monthly or weekly injections.  Current global sales of human growth hormone products are estimated at about $3 billion annually.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, biobetter, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in clinical development, and interferon beta, factor VII, factor IX and erythropoietin, which are in preclinical development, as well as GLP-1 and other therapeutic peptides.  For more information on PROLOR, visit http://www.prolor-biotech.com/.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “intends,” “estimates,” “suggests” and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR’s long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR’s business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel‘s Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR’s filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

Tuesday, June 29th, 2010 Uncategorized Comments Off on PROLOR Biotech (PBTH) Granted EU GMP Certification for Lead Candidate hGH-CTP

South Hampton Resources Signs Five-Year Agreement for Hydrocarbon Supply

SUGARLAND, Texas, June 29 /PRNewswire-FirstCall/ — South Hampton Resources, Inc., an affiliate of Arabian American Development Co. (Nasdaq:ARSDNews), today announced that it has signed a five-year replacement contract with an affiliate of a Fortune 100 company that allows sales in excess of $15 million per year based on current market values, which represents a continuing business relationship with a current purchaser. The contract includes several different hydrocarbons that will be supplied to multiple plant locations for the customer within North America.

Mark Williamson, Vice President, Marketing, South Hampton Resources, ARSD’s Specialty Petrochemicals business, commented, “The five-year new replacement agreement reflects South Hampton’s long-term business relationship with the customer, superior product quality, our fast and flexible customer service and our market leadership. In addition, by negotiating a term agreement based on market indices, we will be able to minimize the impact to gross margins more effectively as market conditions change over the life of the agreement and is in-line with our stated objective to move larger customers to these types of pricing structures.”

About Arabian American Development Company (ARSD)

ARSD owns and operates a petrochemical facility located in southeast Texas just north of Beaumont which specializes in high purity petrochemical solvents and other solvent type manufacturing. The Company is also the original developer and now a 41% investor in a Saudi Arabian joint stock company involving a mining project in the Al-Masane area of Saudi Arabia which is currently under construction. The mine is scheduled to be in production in 2011 and will produce economic quantities of zinc, copper, gold, and silver.

Safe Harbor

Statements in this release that are not historical facts are forward looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward looking statements are based upon management’s belief as well as assumptions made by and information currently available to management. Because such statements are based upon expectations as to future economic performance and are not statements of fact, actual results may differ from those projected. These risks, as well as others, are discussed in greater detail in Arabian American’s filings with the Securities and Exchange Commission, including Arabian American’s Annual Report on Form 10-K for the year ended December 31,  2009 and the Company’s subsequent Quarterly Reports on Form 10-Q.

Tuesday, June 29th, 2010 Uncategorized Comments Off on South Hampton Resources Signs Five-Year Agreement for Hydrocarbon Supply

Tesla (TSLA) Opens Showroom in Copenhagen

Jun. 29, 2010 (Business Wire) — Electric vehicle manufacturer Tesla Motors will open its newest showroom this week in Denmark’s largest city.

Tesla’s 13th worldwide store is at Bredgade 35, in the heart of Copenhagen, recognized internationally as one of the world’s most environmentally friendly places. Copenhagen, which hosted the most recent UN Conference on Climate Change, generates a growing percentage of its grid’s energy from the famous offshore wind farm at Middelgrunden. The city is working to reduce CO2 emissions by 20 percent by 2015.

“People in Denmark believe in social responsibility, and the Tesla Roadster is the only electric vehicle that combines a world-class sports car with their values of environmental stewardship,” said Cristiano Carlutti, Tesla’s Vice President for European Sales and Operations. “We are thrilled that customers in Denmark and throughout Scandinavia have embraced not only the Roadster but the core business philosophy of Tesla Motors.”

The US Ambassador to Denmark, Laurie S. Fulton, will kick off festivities at 2 p.m. July 1. Tesla is hosting a media open house from 2 p.m. to 5 p.m., including test drives, executive interviews and surprise guests. An invitation-only VIP gala will follow in the evening, and the store will be open for prospective customers to test-drive the Roadster throughout the weekend.

The zero-emission Roadster does not pay traditional vehicle taxes in Denmark. By contrast, people who buy conventional petroleum-burning cars pay up to 180 percent car tax on top of the manufacturers’ sales price. Tax waivers combined with expensive gasoline prices mean that the Tesla Roadster is a tremendous value relative to comparable cars in Denmark.

Tesla’s founding goal is to produce energy-efficient cars for mass-market, mainstream consumers. Tesla deliberately started with the Roadster, a premium sports car aimed at affluent “thought leaders,” in order to establish a proof of technology and shatter the prevailing stereotype that electric cars are underpowered and unfashionable. Based in California’s Silicon Valley, Tesla has already delivered more than 1,000 cars in at least 25 countries, and has forged strategic alliances with Daimler and Toyota to produce zero-emission cars.

The Roadster accelerates faster than other sports car in its price class yet has zero tailpipe emissions. It consumes no petroleum and plugs into conventional sockets – at owners’ garages or offices, hotels, parking decks or at a growing number of charging stations throughout Scandinavia. It’s the only sports car that can be fully or partially recharged by renewable energy – and several regional customers charge on 100 percent solar power from their photovoltaic panels or wind power from turbines.

About Tesla

Tesla has already delivered more than 1,000 zero-emission cars in at least 25 countries. With a relentless focus on customer service, Tesla sells cars directly to clients, both online and at four showrooms in Europe: Zurich, Munich, Monaco and London, and in Copenhagen starting July 1. Tesla has eight additional showrooms in North America.

Tuesday, June 29th, 2010 Uncategorized Comments Off on Tesla (TSLA) Opens Showroom in Copenhagen

Eastern Bank Corp. (WAIN) Announces Agreement to Acquire Wainwright Bank & Trust Company

BOSTON, June 29 /PRNewswire-FirstCall/ — Eastern Bank Corporation signed a definitive agreement to acquire Wainwright Bank & Trust Company (Nasdaq: WAIN) in an all-cash transaction valued at approximately $163 million, the banks announced today.

Under the terms of the transaction, shareholders of Wainwright Bank & Trust Company will be entitled to receive $19.00 in cash in exchange for each share of Wainwright Bank & Trust Company common stock and common stock equivalents outstanding.

The merger will combine two banks focused on serving their communities, while providing enhanced convenience for customers of both organizations.  The combined organization will have more than 90 retail banking offices serving people and businesses across eastern Massachusetts, including 22 offices in the Boston metro area.

“It is a pleasure to join forces with an organization that is an acknowledged leader in many social justice issues, including development of affordable housing, support of community health centers, and leadership in improving the environment and protecting the rights of all,” said Richard E. Holbrook, chairman and CEO of Eastern Bank.  “By combining our two organizations, we will broaden our horizons and do even more to make our communities a better place to work and live, while providing our customers with top-notch banking, investment and insurance services. I cannot think of a more appropriate partnership than this one combining a 192-year-old mutual company with the banking industry’s leader on socially progressive issues.”

At March 31, 2010, Eastern Bank Corporation’s consolidated assets were approximately $6.6 billion and Wainwright Bank & Trust Company had assets of approximately $1.0 billion.  At March 31, 2010, Wainwright Bank & Trust Company and Eastern Bank were both considered well-capitalized under applicable regulatory capital guidelines, and Eastern Bank will be well-capitalized under such standards upon completion of the transaction.

The completion of the merger is subject to certain customary conditions, including the approval of the shareholders of Wainwright Bank & Trust Company and the receipt of regulatory approvals. Completion of the merger is expected to occur in the fourth quarter of calendar year 2010.  It is expected that Wainwright Bank & Trust Company will remain as a separate subsidiary of Eastern Bank Corporation for a transition period before it is merged into Eastern Bank.

Jan A. Miller, President and CEO of Wainwright Bank & Trust Company, stated, “The merger combines two banks with strong traditions of commitment to our customers, employees and the communities we serve.  We are pleased that Eastern will maintain and continue to build upon Wainwright’s community development lending initiatives and deep commitment to issues of social justice.”

Annually Eastern Bank Corporation has donated an average in excess of 10 percent of its net income to charity, totaling more than $50 million in the past decade. These funds are managed by the Eastern Bank Charitable Foundation, which in turn will donate about $2.3 million to not-for-profits across eastern Massachusetts in 2010, continuing its tradition of giving back to the communities it serves. After the merger, Eastern Bank intends to continue to present the Wainwright Social Justice Award that has been a hallmark of Wainwright’s commitment to the community.

In April, Eastern Bank earned “Highest Customer Satisfaction in Retail Banking in the New England Region” for the J.D. Power and Associates 2010 Retail Banking Satisfaction StudySM.*  In December, Eastern Bank was named one of the top 10 businesses of the decade by the Boston Business Journal.   And both banks were among The Boston Globe’s “Top 100 Places to Work” in 2009.

Upon closing, Robert A. Glassman and John M. Plukas, Co-founders and current Co-chairmen of Wainwright Bank & Trust Company, are expected to join the board of directors of Eastern Bank Corporation and Eastern Bank.  Jan A. Miller, President and Chief Executive Officer of Wainwright Bank & Trust Company, will become President of Eastern Bank Corporation and Executive Vice President of Eastern Bank.

RBC Capital Markets acted as financial advisor to Eastern Bank Corporation, and Sandler O’Neill + Partners, L.P. acted as financial advisor to Wainwright Bank & Trust Company and rendered a fairness opinion to the Board of Directors of Wainwright Bank & Trust Company in conjunction with this transaction.  Nutter McClennen & Fish LLP served as legal counsel to Eastern Bank Corporation and Kilpatrick Stockton LLP served as legal counsel to Wainwright Bank & Trust Company.

About Eastern Bank Corporation

Founded in 1818 and based in Boston, Eastern Bank is the largest independent and mutually owned bank in New England, with almost $7.0 billion in assets and more than 80 branches serving communities from the Merrimack Valley to Cape Cod.  Eastern Bank offers banking, investments and insurance all under one roof, and prides itself on working harder to understand its customers’ needs so it can deliver these services in a committed and personal way.  Eastern Bank includes Eastern Wealth Management, Eastern Insurance and Fantini & Gorga, a real estate advisory firm. For more information, visit www.easternbank.com.

* Eastern Bank received the highest numerical score among retail banks in the New England region in the proprietary J.D. Power and Associates 2010 Retail Banking Satisfaction StudySM. Study based on 47,673 total responses measuring 9 providers in the New England region (CT, MA, ME, NH, RI, VT) and measures opinions of consumers with their primary banking provider.  Proprietary study results are based on experiences and perceptions of consumers surveyed in January 2010.  Your experiences may vary.  For more information, visit www.jdpower.com.

About Wainwright Bank & Trust Company

Wainwright Bank & Trust Company was founded in 1987.  With $1 billion in assets and 12 branches serving Greater Boston, Wainwright Bank is widely recognized as the country’s leading socially progressive bank. It has committed over $800 million in loans to socially responsible development projects including affordable housing, environmental protection, HIV/AIDS services, homeless shelters, immigration services and more. The Bank was named the “ultimate high-purpose company” in a recently published book by award-winning author, Christine Arena, entitled “The High-Purpose Company: The Truly Responsible (and Highly Profitable) Firms That Are Changing Business Now”. With Boston branches in the Financial District, Back Bay/South End, Jamaica Plain, Dorchester, Cambridge branches within Harvard Square, Kendall Square, Central Square and the Fresh Pond Mall, its Watertown, Somerville, Newton, and Brookline branches, Wainwright is strategically positioned to provide consumer and commercial mortgages, loans, and deposit services to individuals, families, businesses, and non-profit organizations.

This Press Release contains statements relating to future results of Eastern Bank and Wainwright Bank & Trust Company (including certain projections and business trends) that are considered “forward-looking statements” as defined in the Private Securities Legislation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to changes in political and economic conditions, interest rate fluctuations, competitive product and pricing pressures within the  market of the parties, bond market fluctuations, personal and corporate customers’ bankruptcies, and inflation, as well as other risks and uncertainties.

Tuesday, June 29th, 2010 Uncategorized Comments Off on Eastern Bank Corp. (WAIN) Announces Agreement to Acquire Wainwright Bank & Trust Company

PolyMet (PLM) EIS-Path Forward to Completion Announced

HOYT LAKES, MINNESOTA, Jun. 25, 2010 (Marketwire) — PolyMet Mining Corp. (TSX:POM)(NYSE Amex:PLM) (“PolyMet” or the “Company”) announced today that the state and federal government agencies responsible for the Environmental Impact Statement (EIS) reviewing PolyMet’s copper-nickel-precious metals project will complete the EIS process by preparing a supplemental draft EIS that incorporates the proposed US Forest Service (USFS) land exchange and expands government agency cooperation.

The USFS will join the US Army Corps of Engineers (USACE) as a federal co-lead agency through the completion of the EIS process. In addition, the U.S. Environmental Protection Agency (EPA) will join the effort as a cooperating agency. The Minnesota Department of Natural Resources (DNR) remains the state co-lead agency.

The supplemental draft EIS will:

--  Define and analyze a specific project alternative as it is expected to
be built
--  Fully incorporate the proposed land exchange with the USFS into a
consolidated EIS process
--  Reflect applicable comments received on the Draft EIS from the public
and government agencies including appropriate recommendations from EPA
--  Integrate key project improvements, modifications, alternatives, and
mitigation measures to minimize environmental impacts

LaTisha Gietzen, Vice President of Public, Government and Environmental Affairs, stated: “We are pleased the US Forest Service and the EPA are more formally involved in the EIS process. The agencies are actively engaged in planning an effective and efficient path forward to completion of environmental review.”

Background

The PolyMet project comprises the Erie Plant and the nearby NorthMet copper-nickel-precious metals ore-body, located near Hoyt Lakes in the established mining district of the Mesabi Iron Range in northeastern Minnesota.

PolyMet began the environmental review process in 2004. The analysis is contained in more than 100 technical studies totaling approximately 14,000 pages that were the basis for the draft EIS. The milestones achieved to date are shown in the diagram below.

To view diagram please click on the following link: http://media3.marketwire.com/docs/Diagram1.pdf

In November 2009 the DNR and the USACE published the draft EIS reviewing PolyMet’s project, followed by a 90-day public comment period. The agencies received more than 3,700 separate submissions, including comments by the EPA and other government agencies. At the same time as the draft EIS was being prepared and was on public notice, PolyMet was working on a land exchange with the USFS, which holds certain surface rights at the NorthMet mine site.

The supplemental draft EIS will build upon the existing draft EIS by incorporating appropriate comments received on the draft EIS, include project improvements and roll in the USFS land exchange. The following diagram illustrates how the environmental review process will move forward.

To view diagram please click on the following link: http://media3.marketwire.com/docs/Diagram2.pdf

PolyMet anticipates that the lead agencies will establish the timeline for publication of the supplemental draft EIS when they have agreed on all the details of the project. Once the supplemental draft EIS is completed, it will be made available for public review prior to preparation of the final EIS. Completion of the final EIS and a subsequent Adequacy Decision by the DNR and Record of Decision by the federal agencies are necessary before the land exchange can occur and various permits required to construct and operate the project can be issued.

Joe Scipioni, President and CEO of PolyMet, said: “The government agencies involved have put a great deal of effort into developing this plan that incorporates and consolidates the land exchange into the EIS process, considers the EPA’s recommendations, and strengthens the partnership among state and federal agencies. The supplemental draft EIS will streamline the process moving forward and provide clarity as to the specific project that we plan to build.”

He continued, “The supplemental draft EIS will describe a project that can be built in a way that not only creates the much-needed jobs but also protects our environment and natural resources.”

See DNR news release: http://news.dnr.state.mn.us/index.php/2010/06/24/supplemental-draft-eis-to-be-prepared-for-proposed-northmet-mining-project/#more-43684

USACE news release: http://www.mvp.usace.army.mil/regulatory/

About PolyMet

PolyMet Mining Corp. (www.polymetmining.com) is a publicly-traded mine development company that controls 100% of the NorthMet copper-nickel-precious metals ore body through a long-term lease and owns 100% of the Erie Plant, a large processing facility located approximately six miles from the ore body in the established mining district of the Mesabi Range in northeastern Minnesota. PolyMet Mining Corp. has completed its Definitive Feasibility Study and is seeking environmental and operating permits to enable it to commence production. The NorthMet project is expected to require approximately one million man-hours of construction labor and create at least 400 long-term jobs, a level of activity that will have a significant multiplier effect in the local economy.

POLYMET MINING CORP.

Joe Scipioni, President

This news release contains certain forward-looking statements concerning anticipated developments in PolyMet’s operations in the future. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, “projects”, “plans”, and similar expressions, or statements that events, conditions or results “will”, “may”, “could”, or “should” occur or be achieved or their negatives or other comparable words. These forward-looking statements may include statements regarding our beliefs related to the expected proceeds and closing of the registered direct offering, exploration results and budgets, reserve estimates, mineral resource estimates, work programs, capital expenditures, actions by government authorities, including changes in government regulation, the market price of natural resources, costs, or other statements that are not a statement of fact. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those in the forward-looking statements due to risks facing PolyMet or due to actual facts differing from the assumptions underlying its predictions. PolyMet’s forward-looking statements are based on the beliefs, expectations and opinions of management on the date the statements are made, and PolyMet does not assume any obligation to update forward-looking statements if circumstances or management’s beliefs, expectations and opinions should change.

Specific reference is made to PolyMet’s most recent Annual Report on Form 20-F for the fiscal year ended January 31, 2010 and in our other filings with Canadian securities authorities and the Securities and Exchange Commission, including our Report on Form 6-K providing information with respect to our operations for the three months ended April 30, 2010 for a discussion of some of the risk factors and other considerations underlying forward-looking statements.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Monday, June 28th, 2010 Uncategorized Comments Off on PolyMet (PLM) EIS-Path Forward to Completion Announced

Cheniere Partners and Cheniere Energy, Inc. (CQP) Agree to Restructure Cheniere Marketing TUA Arrangements

HOUSTON, June 28 /PRNewswire-FirstCall/ — Cheniere Energy Partners, L.P. (“Cheniere Partners”) (NYSE Amex: CQP) announced today that its direct subsidiary, Cheniere Energy Investments, LLC (“Investments”), has accepted the assignment of the existing terminal use agreement (“TUA”) with Sabine Pass LNG, L.P. (“Sabine”) from Cheniere Marketing, LLC (“Marketing”), a subsidiary of Cheniere Energy, Inc. and concurrently entered into a Variable Capacity Rights Agreement (“VCRA”) with Marketing.  The TUA provides 2.0 Bcf/d of sendout capacity and 6.9 Bcfe of storage capacity at the Sabine Pass LNG receiving terminal.

Investments will assume the TUA effective July 1, 2010.  Under the terms of the new VCRA, Marketing will have the right to utilize the services and other rights at the Sabine Pass LNG receiving terminal available under the TUA assigned to Investments and to commercialize these rights on Investments’ behalf.  In consideration of these rights, Marketing will pay Investments a fee for each cargo delivered to the Sabine Pass facility equal to eighty percent of the expected positive gross margin to be received with respect to each cargo.  These transactions do not impact the previously announced arrangement between Marketing and JPMorgan LNG Co. or any existing agreements with other counterparties.

Subsequent to the assignment of the TUA, distributions on subordinated units will only be made to the extent Cheniere Partners generates distributable cash flows above the initial quarterly distribution requirement for its common unitholders and general partner.  Such distributable cash flows could be generated through new business development or fees received from Cheniere Marketing under the VCRA.  Prior to these transactions, Cheniere Partners had been using cash paid under the Marketing TUA to make distributions on the subordinated units.  Consequently, the ending of the subordination period and the conversion of subordinated units into common units will depend upon future business development and is no longer expected to occur as early as the second quarter of 2012 as previously estimated.

This transaction is not expected to impact the ability of Cheniere Partners to pay the initial quarterly distribution to its common unitholders and general partner.  In order to provide additional distribution coverage, Cheniere Partners and Cheniere have agreed to amend the payment terms of the management services agreement under which a Cheniere subsidiary provides certain management, accounting and other related services to Cheniere Partners, which will subordinate the payment of the services fees to the distributions to the common unitholders and general partner.

Cheniere Partners owns 100 percent of the Sabine Pass LNG receiving terminal located in western Cameron Parish, Louisiana on the Sabine Pass Channel. Construction is complete and the terminal is now operating with sendout capacity of 4.0 Bcf/d and storage capacity of 16.9 Bcfe.  Additional information about Cheniere Energy Partners, L.P. may be found on its website: http://www.cheniereenergypartners.com/.

For additional information, please refer to the Cheniere Energy Partners, L.P. Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission.

This press release contains certain statements that may include “forward-looking statements” within the meanings of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, (i) statements regarding Cheniere Energy Partners’ business strategy, plans and objectives and (ii) statements expressing beliefs and expectations regarding the development of Cheniere Energy Partners’ LNG receiving terminal business. Although Cheniere Energy Partners believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Cheniere Energy Partners’ actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in Cheniere Energy Partners’ periodic reports that are filed with and available from the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, Cheniere Energy Partners does not assume a duty to update these forward-looking statements.

Monday, June 28th, 2010 Uncategorized Comments Off on Cheniere Partners and Cheniere Energy, Inc. (CQP) Agree to Restructure Cheniere Marketing TUA Arrangements

ZAGG (ZAGG) to Introduce invisibleSHIELD Dry(TM) Nationwide Exclusively Through AT&T

Jun. 28, 2010 (Business Wire) — ZAGG Inc. (NASDAQ: ZAGG) (www.ZAGG.com), a leading producer of electronics accessories for protecting and enhancing the mobile experience, including the popular invisibleSHIELD™, ZAGGbuds™, and ZAGGsparq™ brands, announced today that AT&T will be the first to offer the new invisibleSHIELD Dry™. ZAGG’s new invisibleSHIELD Dry is available exclusively at AT&T stores nationwide.

“We are thrilled to offer invisibleSHIELD Dry to AT&T customers and provide them with our world-class scratch protection and electronics accessories,” said Robert G. Pedersen II, CEO and co-founder of ZAGG.

The invisibleSHIELD is a military-grade, virtually invisible, and indestructible film that protects thousands of gadgets from bumps, scratches, and dings with a lifetime guarantee. The invisibleSHIELD Dry™ is the next generation of ZAGG’s flagship product, and takes their original, award-winning scratch protection to a new level with the same protection in a dry-installed film.

“We look forward to bringing ZAGG’s invisibleSHIELD Dry technology to our customers,” said Michael Cowan, Accessories Business Director for AT&T.

“ZAGG has been developing and perfecting the invisibleSHIELD Dry over the past year, and we are very excited to introduce it,” said Derek Smith, Vice President of Sales for ZAGG. “Made from the same amazing material, the invisibleSHIELD Dry installs without moisture, filling a demand currently unmet in the marketplace.”

The invisibleSHIELD Dry is available in AT&T stores nationwide. For more information about ZAGG or any of their products, please visit ZAGG.com.

About ZAGG Inc.:

ZAGG is dedicated to protecting and enhancing the mobile experience. ZAGG designs, manufactures, and distributes protective clear coverings and accessories for consumer electronic and hand-held devices, worldwide, under the brand names invisibleSHIELD™, ZAGGbuds™, and ZAGGsparq™. ZAGG has also introduced appSpace, a powerful recommendation engine for the fast-growing mobile app market, combined with the networking power of social media. The invisibleSHIELD is a protective, high-tech patented film covering, designed for iPods, laptops, cell phones, digital cameras, PDAs, watch faces, GPS systems, gaming devices, and other items. The patent-pending invisibleSHIELD application of clear protective film covering a device is the first scratch protection solution of its kind on the market, and has sold millions of units. Currently, ZAGG offers over 4,000 precision pre-cut designs with a lifetime replacement warranty through ZAGG.com, major retailers like Best Buy, Radio Shack, and Cricket, resellers, college bookstores, Mac stores, mall kiosks, and other online retailers. The company continues to increase its product lines to offer additional electronic accessories and services to its tech-savvy customer base, including upcoming technologies like ZAGGbox(TM), introduced at CES 2010, and HzO(TM), a breakthrough gadget waterproofing technology. For more product or investor information please visit the company’s web site at www.ZAGG.com.

Safe Harbor Statement:

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in filings made by the company with the Securities and Exchange Commission.

Monday, June 28th, 2010 Uncategorized Comments Off on ZAGG (ZAGG) to Introduce invisibleSHIELD Dry(TM) Nationwide Exclusively Through AT&T

Orexigen(R) Therapeutics (OREX) Announces That Contrave(R) Reduced Depression Scores and Body Weight

ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from a 24-week open-label study demonstrating that treatment with Contrave® resulted in significant improvements in depressive symptoms that was accompanied by weight loss and improved control of eating in overweight and obese patients with major depression.

The primary endpoint of the study was the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) at 12 weeks on an intent-to-treat (ITT) basis.  Treatment with Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) resulted in the MADRS score decreasing from an average of 23.7 at baseline (consistent with moderate depression) to 10.5 (mild depression) (p<0.001) at week 12 and further decreasing to 8.4 (remission) at week 24 (p<0.001).  Patients who completed the study lost an average of 9.2% of total body weight and reported substantial reductions in hunger, strength and frequency of food cravings and demonstrated improved control of eating.

“Recent reports in the literature show that the risk of depression is higher in obese people and, at the same time, depression has been associated with increased obesity.  In addition, obese women are more than twice as likely to be depressed as non-obese women.  In this context, clinicians are in need of new tools to treat obese patients suffering from this common co-morbidity,” said Dr. Susan McElroy, M.D., Lindner Center of HOPE, Mason, Ohio.  “This study is the first step in assessing the value of Contrave in this important patient population and these positive results should encourage additional investigation.”

In this study, the most common adverse events were nausea, constipation, headache and insomnia, and, in general, were consistent with past experience in the COR program.  There were no serious adverse events reported by the investigator as related or possibly related to Contrave in the trial.

About Contrave

Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity. The two components of this combination therapy act in a complementary manner in the central nervous system. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior.  In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating.

The U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

About the Contrave Clinical Development Program

All four trials in the COR Phase 3 program (COR-I, COR-II, COR-BMOD and COR-Diabetes) were randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in body weight compared to placebo. Secondary endpoints included multiple measures of cardiometabolic risk, quality of life, control of eating, and glycemic control.  Contrave was generally well tolerated.  The safety and tolerability profile of Contrave in the clinical development program was consistent with the safety profile of the constituent components, which have been in use for other indications for over 20 years.  The most frequent treatment-emergent adverse events in patients treated with Contrave were nausea, constipation, headache, vomiting and dizziness.  These were mostly mild to moderate in severity, transient, and typically occurred during the first weeks of treatment.  Most common adverse events leading to discontinuation with Contrave were nausea, headache, dizziness and vomiting.  Treatment with Contrave was not associated with increases in adverse event reports of depression or suicidal ideation compared to placebo.  Mean blood pressure with Contrave was generally unchanged from baseline to endpoint.  Placebo patients experienced decreases in blood pressure from baseline to endpoint of approximately 2mmHg.  Greater weight loss correlated with greater reductions in blood pressure in both Contrave and placebo patients, suggesting that the expected relationship between weight loss and blood pressure was maintained.  Importantly, normal circadian blood pressure patterns were preserved with Contrave.  There was an increase in pulse of about one beat per minute in patients taking Contrave.  Serious events were reported infrequently and included events of cholecystitis (Contrave 0.2%, PBO <0.1%), seizure (<0.1%, 0%) and major cardiovascular events (<0.1%, <0.1%).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.  Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, approval for Contrave and the Company’s belief that this product candidate may be an important therapeutic option in the treatment of obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave; the potential for adverse safety findings relating to Contrave; and other risks described in the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 10, 2010 and is available from the SEC’s website (www.sec.gov) and on our website (www.orexigen.com) under the heading “Investor Relations”. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Monday, June 28th, 2010 Uncategorized Comments Off on Orexigen(R) Therapeutics (OREX) Announces That Contrave(R) Reduced Depression Scores and Body Weight

Oxygen Biotherapeutics (OXBT) Set to Join Russell Microcap Index

DURHAM, N.C., June 25, 2010 (GLOBE NEWSWIRE) — Oxygen Biotherapeutics, Inc. (Nasdaq:OXBTNews) is set to join the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes today. Oxygen Biotherapeutics was named on a preliminary list of additions posted on http://www.russell.com/. Oxygen Biotherapeutics is engaged in the business of developing proprietary products that deliver oxygen to tissues in the body.

According to Russell Investments, the Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It makes up less than 3% of the U.S. equity market. It includes 1,000 of the smallest securities in the small-cap Russell 2000(R) Index based on a combination of their market cap and current index membership and it includes the next 1,000 securities. The Russell Microcap Index is constructed to provide a comprehensive and unbiased barometer for the microcap segment trading on national exchanges, while excluding lesser-regulated OTC bulletin board securities and pink-sheet stocks due to their failure to meet national exchange listing requirements. The Russell Microcap Index is completely reconstituted annually to ensure larger stocks do not distort performance and characteristics of the true microcap opportunity set. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Total returns data for the Russell Microcap Index and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.

“Inclusion in the Russell Microcap Index is an important achievement for our company. It is a valuable component for increasing awareness of our progress and achievements among a wide range of investors,” said Chairman and Chief Executive Officer Chris Stern.

About Russell Investments

Founded in 1936, Russell Investments is a global financial services firm that serves institutional investors, financial advisers and individuals in more than 40 countries. Russell launched its family of indexes in 1984 to more accurately measure U.S. market segments and better track investment manager behavior for its investment management and consulting businesses. For more information, visit http://www.russell.com/.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte(R) that is being formulated for both intravenous and topical delivery. In April, the company launched its first cosmetic product, Dermacyte(R) Oxygen Concentrate. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing. More information is available at http://www.oxybiomed.com/ or http://www.buydermacyte.com/.

The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. These statements include the expansion of development of the Oxycyte product line and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company’s control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current report on Form 8-K filed on May 4, 2010. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Friday, June 25th, 2010 Uncategorized Comments Off on Oxygen Biotherapeutics (OXBT) Set to Join Russell Microcap Index

PolyMet (PLM) EIS-Path Forward to Completion Announced

HOYT LAKES, MINNESOTA–(Marketwire – 06/25/10) – PolyMet Mining Corp. (TSX:POMNews)(AMEX:PLMNews) (“PolyMet” or the “Company”) announced today that the state and federal government agencies responsible for the Environmental Impact Statement (EIS) reviewing PolyMet’s copper-nickel-precious metals project will complete the EIS process by preparing a supplemental draft EIS that incorporates the proposed US Forest Service (USFS) land exchange and expands government agency cooperation.

The USFS will join the US Army Corps of Engineers (USACE) as a federal co-lead agency through the completion of the EIS process. In addition, the U.S. Environmental Protection Agency (EPA) will join the effort as a cooperating agency. The Minnesota Department of Natural Resources (DNR) remains the state co-lead agency.

The supplemental draft EIS will:

 

--  Define and analyze a specific project alternative as it is expected to
    be built
--  Fully incorporate the proposed land exchange with the USFS into a
    consolidated EIS process
--  Reflect applicable comments received on the Draft EIS from the public
    and government agencies including appropriate recommendations from EPA
--  Integrate key project improvements, modifications, alternatives, and
    mitigation measures to minimize environmental impacts

LaTisha Gietzen, Vice President of Public, Government and Environmental Affairs, stated: “We are pleased the US Forest Service and the EPA are more formally involved in the EIS process. The agencies are actively engaged in planning an effective and efficient path forward to completion of environmental review.”

Background

The PolyMet project comprises the Erie Plant and the nearby NorthMet copper-nickel-precious metals ore-body, located near Hoyt Lakes in the established mining district of the Mesabi Iron Range in northeastern Minnesota.

PolyMet began the environmental review process in 2004. The analysis is contained in more than 100 technical studies totaling approximately 14,000 pages that were the basis for the draft EIS. The milestones achieved to date are shown in the diagram below.

To view diagram please click on the following link: http://media3.marketwire.com/docs/Diagram1.pdf

In November 2009 the DNR and the USACE published the draft EIS reviewing PolyMet’s project, followed by a 90-day public comment period. The agencies received more than 3,700 separate submissions, including comments by the EPA and other government agencies. At the same time as the draft EIS was being prepared and was on public notice, PolyMet was working on a land exchange with the USFS, which holds certain surface rights at the NorthMet mine site.

The supplemental draft EIS will build upon the existing draft EIS by incorporating appropriate comments received on the draft EIS, include project improvements and roll in the USFS land exchange. The following diagram illustrates how the environmental review process will move forward.

To view diagram please click on the following link: http://media3.marketwire.com/docs/Diagram2.pdf

PolyMet anticipates that the lead agencies will establish the timeline for publication of the supplemental draft EIS when they have agreed on all the details of the project. Once the supplemental draft EIS is completed, it will be made available for public review prior to preparation of the final EIS. Completion of the final EIS and a subsequent Adequacy Decision by the DNR and Record of Decision by the federal agencies are necessary before the land exchange can occur and various permits required to construct and operate the project can be issued.

Joe Scipioni, President and CEO of PolyMet, said: “The government agencies involved have put a great deal of effort into developing this plan that incorporates and consolidates the land exchange into the EIS process, considers the EPA’s recommendations, and strengthens the partnership among state and federal agencies. The supplemental draft EIS will streamline the process moving forward and provide clarity as to the specific project that we plan to build.”

He continued, “The supplemental draft EIS will describe a project that can be built in a way that not only creates the much-needed jobs but also protects our environment and natural resources.”

See DNR news release: http://news.dnr.state.mn.us/index.php/2010/06/24/supplemental-draft-eis-to-be-prepared-for-proposed-northmet-mining-project/#more-43684

USACE news release: http://www.mvp.usace.army.mil/regulatory/

About PolyMet

PolyMet Mining Corp. (http://www.polymetmining.com/) is a publicly-traded mine development company that controls 100% of the NorthMet copper-nickel-precious metals ore body through a long-term lease and owns 100% of the Erie Plant, a large processing facility located approximately six miles from the ore body in the established mining district of the Mesabi Range in northeastern Minnesota. PolyMet Mining Corp. has completed its Definitive Feasibility Study and is seeking environmental and operating permits to enable it to commence production. The NorthMet project is expected to require approximately one million man-hours of construction labor and create at least 400 long-term jobs, a level of activity that will have a significant multiplier effect in the local economy.

POLYMET MINING CORP.

Joe Scipioni, President

This news release contains certain forward-looking statements concerning anticipated developments in PolyMet’s operations in the future. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, “projects”, “plans”, and similar expressions, or statements that events, conditions or results “will”, “may”, “could”, or “should” occur or be achieved or their negatives or other comparable words. These forward-looking statements may include statements regarding our beliefs related to the expected proceeds and closing of the registered direct offering, exploration results and budgets, reserve estimates, mineral resource estimates, work programs, capital expenditures, actions by government authorities, including changes in government regulation, the market price of natural resources, costs, or other statements that are not a statement of fact. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those in the forward-looking statements due to risks facing PolyMet or due to actual facts differing from the assumptions underlying its predictions. PolyMet’s forward-looking statements are based on the beliefs, expectations and opinions of management on the date the statements are made, and PolyMet does not assume any obligation to update forward-looking statements if circumstances or management’s beliefs, expectations and opinions should change.

Specific reference is made to PolyMet’s most recent Annual Report on Form 20-F for the fiscal year ended January 31, 2010 and in our other filings with Canadian securities authorities and the Securities and Exchange Commission, including our Report on Form 6-K providing information with respect to our operations for the three months ended April 30, 2010 for a discussion of some of the risk factors and other considerations underlying forward-looking statements.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Friday, June 25th, 2010 Uncategorized Comments Off on PolyMet (PLM) EIS-Path Forward to Completion Announced

Netlist (NLST) Set to Join Russell Microcap(R) Index

IRVINE, Calif., June 25 /PRNewswire-FirstCall/ — Netlist, Inc. (Nasdaq:NLSTNews), a designer and manufacturer of high-performance memory subsystems, today announced that it will join the Russell Microcap® Index when Russell Investments reconstitutes its family of U.S. indexes after the close of the U.S. markets today, according to a preliminary list of additions posted June 11 on http://www.russell.com/.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.  Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Netlist Chief Executive Officer C.K. Hong said, “We are pleased to be included in the Russell Microcap Index.  The inclusion in this index increases our visibility in the investment community and will contribute to our efforts to increase shareholder value as we move to market our two emerging technology platforms, HyperCloud™ and NetVault™.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.  An industry-leading $3.9 trillion in assets currently are benchmarked to them.

Annual reconstitution of Russell Indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000® Index and Russell Microcap.  These investment tools originated from Russell’s multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell Microcap and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.

About Russell:

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $179 billion in assets under management as of March 31 2010, and serves individual, institutional and advisor clients in more than 40 countries.  Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Netlist:

Netlist, Inc. designs and manufactures high-performance, logic-based memory subsystems for the server and high-performance computing and communications markets.  The Company’s memory subsystems are developed for applications in which high-speed, high-capacity memory, enhanced functionality, small form factor, and heat dissipation are key requirements.  These applications include tower-servers, rack-mounted servers, blade servers, high-performance computing clusters, engineering workstations, and telecommunication equipment.  Netlist was founded in 2000 and is headquartered in Irvine, California with manufacturing facilities in Suzhou, People’s Republic of China.

Netlist is listed on the NASDAQ stock exchange under the ticker “NLST.”  More information can be found on the Company’s web site: http://www.netlist.com/.

Safe Harbor Statement

This news release contains forward-looking statements regarding future events and the future performance of Netlist. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expected or projected. These risks and uncertainties include, but are not limited to, continuing development, qualification and volume production of NetVault™ and HyperCloud™; the rapidly-changing nature of technology; risks associated with intellectual property, including the costs and unpredictability of litigation over infringement of our intellectual property; volatility in the pricing of DRAM ICs and NAND; changes in and uncertainty of customer acceptance of, and demand for, our existing products and products under development, including uncertainty of and/or delays in product orders and product qualifications; delays in the Company’s and its customers’ product releases and development; introductions of new products by competitors; changes in end-user demand for technology solutions; the Company’s ability to attract and retain skilled personnel; the Company’s reliance on suppliers of critical components; fluctuations in the market price of critical components; evolving industry standards; and the political and regulatory environment in the People’s Republic of China. Other risks and uncertainties are described in the Company’s annual report on Form 10-K, dated February 19, 2010, and subsequent filings with the U.S. Securities and Exchange Commission made by the Company from time to time. Except as required by law, Netlist undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact: Investor Contact:
Katie Lister Jill Bertotti
Vantage Communications for Netlist Allen & Caron Inc
407-767-0452 x229 949-474-4300
klister@pr-vantage.com jill@allencaron.com
Friday, June 25th, 2010 Uncategorized Comments Off on Netlist (NLST) Set to Join Russell Microcap(R) Index

Empire Resorts (NYNY) Set to Join Russell 3000 Index

MONTICELLO, N.Y.–(BUSINESS WIRE)–Empire Resorts, Inc., (NASDAQ: NYNYNews) today announced it is set to join the broad-market Russell 3000® Index on June 25, 2010, as part of an annual reconstitution of Russell’s U.S. and global equity indexes according to Russell’s preliminary list of additions published June 11, 2010 at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.russell.com&esheet=6340254&lan=en-US&anchor=www.russell.com&index=1&md5=030ca60c0a96816fc9ab57341794ee40. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010 and remain in place for one year.

Empire Resorts expects that inclusion in the Russell 3000® would also result in inclusion in the Russell 2000, which is a subset of the Russell 3000® Index and includes approximately 2,000 of the smaller companies based on their market capitalization. All Russell indexes are sub-indexes of the Global Index. Initial inclusion in the Russell indexes will continue to raise the awareness of Empire Resorts to a wider range of institutions and investors.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in assets are benchmarked to them. Stocks that are added to Russell indexes are often purchased by index funds. Russell’s investment tools originated from Russell’s multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

More information on the reconstitution is available at: http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx

About Russell Investments

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $179 billion in assets under management as of March 31, 2010, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Empire Resorts

Empire Resorts owns and operates the Monticello Casino & Raceway, a harness racing track and casino located in Monticello, New York, and 90 miles from midtown Manhattan. For additional information, please visit http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.empireresorts.com&esheet=6340254&lan=en-US&anchor=www.empireresorts.com&index=6&md5=d3e0ccfe11f265f055273f9ec57ebdaa.

Statements in this press release regarding the Company’s business that are not historical facts are “forward-looking statements” that may involve material risks and uncertainties. The Company wishes to caution readers not to place undue reliance on such forward-looking statements, which statements are made pursuant to the Private Securities Litigation Reform Act of 1994, and as such, speak only as of the date made. For a full discussion of risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report or Form 10-K for the most recently ended fiscal year, as well as the Form 10-Q for the most recently ended fiscal quarter.

Thursday, June 24th, 2010 Uncategorized Comments Off on Empire Resorts (NYNY) Set to Join Russell 3000 Index

Industrial Services of America, Inc. (IDSA) Issues Second Quarter Revenue Guidance

LOUISVILLE, Ky.–(BUSINESS WIRE)–Industrial Services of America, Inc. (NASDAQ: IDSANews), a company that recycles stainless steel, ferrous and non-ferrous scrap metal today announced revenue guidance for the second quarter ending June 30, 2010.

The second quarter is progressing very well and the company expects revenues to be in the range of $82 – $86 million for the quarter compared with $39.1 million of revenues during the second quarter of 2009.

Chairman of the Board, Harry Kletter, will be presenting at the Sidoti Micro-Cap Conference on June 25, 2010 in New York. At the Conference, “investors will have access not only to informative 35-minute presentations, but one-on-one meetings with CEOs and other top executives, contingent upon demand”.

About ISA

Headquartered in Louisville, Kentucky, Industrial Services of America, Inc. buys, processes and markets scrap metals and recyclable materials for domestic users and export markets. Additionally, the company offers commercial, industrial and business customers a variety of programs and equipment to efficiently manage waste. More information about ISA is available at http://www.isa-inc.com.

This news release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ from predicted results. Specific risks include fluctuations in the price of recycled materials, varying demand for waste managing systems, equipment and services, competitive pressures in the stainless steel, ferrous and non-ferrous scrap metal recycling business, competitive pressures in the waste managing business and loss of customers. Further information on factors that could affect the Company’s results is detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to the forward-looking statements.

The Company’s SEC filings are available for review at the Securities and Exchange Commission web site at http://www.sec.gov/edgar/searchedgar/companysearch.html.

Thursday, June 24th, 2010 Uncategorized Comments Off on Industrial Services of America, Inc. (IDSA) Issues Second Quarter Revenue Guidance

EDAP (EDAP) to Distribute Lumenis Urological Lasers in France

Press Release Source: EDAP TMS SA On Thursday June 24, 2010, 9:00 am EDT

LYON, France, June 24, 2010 (GLOBE NEWSWIRE) — EDAP TMS SA (Nasdaq:EDAPNews), the global leader in therapeutic ultrasound, announced today that it has signed an exclusive agreement with Lumenis, GmbH, to distribute Lumenis urological Holmium/Nd:YAG lasers in France, starting June 2010.

This exclusive distribution agreement will allow EDAP to broaden its products portfolio by offering urologists a new and high-end therapeutic option to their existing tools. Lumenis lasers enable precise minimally invasive treatment for a wide variety of urologic conditions such as benign prostatic hyperplasia (BPH) and bladder, urethral and kidney stones. With its strong knowledge of the French urology market and its close relationships with French urologists, EDAP is well positioned to strengthen its leadership in stone management and urology with the addition of Lumenis’ high-end technology lasers.

Marc Oczachowski, CEO, commented, “I am very enthusiastic about adding Lumenis lasers, recognized as top ranked urology lasers, to our product offering in France. For years, EDAP has proven its leadership and track record in selling urological medical devices in France. In addition to representing a new revenue opportunity, the distribution of Lumenis’ lasers in France will reinforce EDAP’s presence in the urological field by further positioning us as one of the major players offering a wide range of minimally-invasive technologies to patients with urological conditions.”

Lloyd Diamond, President EMEA, from Lumenis, added, “We are pleased to enter into this distribution agreement with EDAP. The French urology market is important to Lumenis and we now have the best partner to develop and support it. The combination of EDAP and Lumenis products provides a comprehensive solution to many of the urologists’ stone and prostate needs.”

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

About Lumenis

Lumenis, one of the world’s largest medical laser companies, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has nearly 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light, which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: http://www.lumenis.com.

Thursday, June 24th, 2010 Uncategorized Comments Off on EDAP (EDAP) to Distribute Lumenis Urological Lasers in France

Water Agencies Approve Agreements for Cadiz (CDZI) Water Conservation Project

LOS ANGELES–(BUSINESS WIRE)–Today Cadiz Inc. (NASDAQ: CDZINews) announced that two Southern California water agencies have approved agreements to proceed with the Cadiz Water Conservation & Storage Project (“Cadiz Project”) and participate in the Project’s environmental review. The Boards of Directors of Santa Margarita Water District (“Santa Margarita”) and Three Valleys Municipal Water District (“Three Valleys”), which together serve over 650,000 customers in parts of Orange and Los Angeles Counties, have unanimously approved agreements that commit funds to an environmental review of the Cadiz Project and also grant the agencies the right to acquire a firm annual supply of water once the environmental review is complete.

Under the terms of the agreements, filed today by the Company with the Securities and Exchange Commission (“SEC”), upon completion of the environmental review, each agency has the right to acquire an annual supply of 5,000 acre-feet of water at a pre-determined formula competitive with their incremental cost of new water. Santa Margarita also has the option to purchase an additional 10,000 acre-feet of water per year. In addition, both agencies have options to acquire storage rights in the Cadiz Project that will allow them to manage this supply to complement their other water resources. The Company continues to work with additional water providers interested in acquiring rights to the remaining annual supply conserved by the Project and is in discussions with third parties regarding the storage aspect of the Project.

The two agencies, which signed Letters of Intent with Cadiz in 2009, approved these agreements following an exhaustive due diligence period. This included the recent publication of a comprehensive study of the Project’s aquifer system by environmental firm CH2M Hill. The study, which was peer reviewed and validated by leading groundwater experts, estimates total groundwater in storage in the aquifer system between 17 and 34 million acre-feet, a quantity on par with Lake Mead, the nation’s largest surface reservoir. The study also confirmed a renewable annual supply of native groundwater in the aquifer system currently being lost to evaporation.

After several months of due diligence, we have determined that the Cadiz Project represents a significant and sustainable new water supply opportunity for Southern California that can be obtained without harming other users or the environment,” said Santa Margarita Water District Board Member Saundra F. Jacobs. “By moving ahead with the Project, we are working to drought-proof our agency, ensuring both a steady supply and a reliable bank of storage for the long-term in an environmentally responsible way. We look forward to taking the lead in the environmental review.”

“Cadiz has presented us with a unique opportunity; one that Three Valleys is excited to pursue,” added Bob Kuhn, President of the Three Valleys Municipal Water District Board of Directors. “The Cadiz Project affords us the chance to obtain a completely new, sustainable water supply by saving water otherwise lost to evaporation and at a price competitive with other new sources, enabling us to improve our overall water supply reliability.”

As part of its agreement with Cadiz, Santa Margarita will serve as lead agency for the California Environmental Quality Act (“CEQA”) review process. Three Valleys will also participate as a responsible agency. Both parties have committed funds to the CEQA process and will share in the costs.

“We are pleased that the Project is moving ahead on the strength of sound science and we look forward to the CEQA environmental review process,” said Cadiz General Counsel Scott Slater. “We’ve enjoyed briefing numerous stakeholders and various environmental groups over the past several months about the Project’s new water conservation strategy, and we welcome the chance for a thoughtful, fact-based analysis of the benefits it will bring to Southern California.”

About the Project

Cadiz owns approximately 35,000 acres of land in the Cadiz and Fenner valleys of San Bernardino County, California. This landholding is underlain by an extensive aquifer system offering storage capacity and natural recharge. One of the largest water conservation efforts of its kind, the Cadiz Project will capture and utilize billions of gallons of renewable native groundwater that is currently being lost to evaporation through the aquifer system and yield a sustainable annual supply for subscribers. In addition, the Project offers approximately one million acre feet of storage capacity that can be used to conserve – or “bank” – imported water, virtually eliminating the high rates of evaporative loss suffered by local surface reservoirs.

About Santa Margarita

Santa Margarita is Orange County’s second-largest water district with a 62,000-acre service area that includes residents and businesses in Mission Viejo, Rancho Santa Margarita, Coto de Caza, Las Flores, Ladera Ranch, and Talega. With limited local water supplies, Santa Margarita currently relies upon imports from the Metropolitan Water District of Southern California (MWD) for much of its water supply, in addition to its groundwater reuse and water recycling supply programs.

About Three Valleys

Three Valleys serves cities, water agencies and water districts in eastern Los Angeles County including residents and businesses in Azusa, City of Industry, Covina, Claremont, Diamond Bar, Glendora, La Puente, La Verne, Pomona, Walnut, West Covina, Hacienda Heights and Rowland Heights. Forty percent of its service area receives water from local sources, while the remaining sixty percent is imported from MWD.

About Cadiz

Founded in 1983, Cadiz is a publicly-held renewable resources company that owns 70 square miles of property with significant water resources and clean energy potential in eastern San Bernardino County, California. The Company is engaged in a combination of water conservation and supply, solar energy, and organic farming projects. Last year, Cadiz signed a wide-ranging “Green Compact” to promote environmental conservation and sustainable management practices. Further information can be obtained by visiting http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cadizinc.com&esheet=6339333&lan=en-US&anchor=www.cadizinc.com&index=1&md5=781b00008240e5b8713df0755bd68081.

This release contains forward-looking statements that are subject to significant risks and uncertainties, including statements related to the future operating and financial performance of the Company and the financing activities of the Company. Although the Company believes that the expectations reflected in our forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Factors that could cause actual results or events to differ materially from those reflected in the Company’s forward-looking statements include the Company’s ability to maximize value for Cadiz land and water resources, the Company’s ability to obtain new financing as needed, and other factors and considerations detailed in the Company’s Securities and Exchange Commission filings.

Thursday, June 24th, 2010 Uncategorized Comments Off on Water Agencies Approve Agreements for Cadiz (CDZI) Water Conservation Project

Universal Security Instruments (UUU) Reports Fourth-Quarter and Year-End Results

Press Release Source: Universal Security Instruments, Inc. On Wednesday June 23, 2010, 8:00 am EDT

OWINGS MILLS, Md., June 23 /PRNewswire-FirstCall/ — Universal Security Instruments, Inc. (NYSE Amex: UUU) today announced results for its fourth quarter and fiscal year ended March 31, 2010.

Universal reported fourth quarter net income of $468,223, or $0.20 per basic and diluted share, on sales of $6,301,918.  This compares to net income of $78,150, or $0.03 per basic and diluted share, on sales of $5,928,367 for the comparable period of the previous year.  Included in last year’s results was income from discontinued operations of $41,767.

For the 12 months ended March 31, 2010, sales were $26,439,118 versus $26,097,596 for the same period last year.  The Company reported net earnings of $2,268,048 or $0.95 per basic and diluted share versus net income of $4,865,357 or $1.97 per basic and $1.96 per diluted share for the same period last year.  Included in the March 31, 2009 results was a gain of $3,423,021 from discontinued operations.  The Company’s book value at March 31, 2010 has increased to $10.96 per share versus $9.95 per share at March 31, 2009.

“We are very pleased with the Company’s performance during the past fiscal year, particularly in light of the challenges the economy has created. Included in our results is approximately $500,000 of research and development expenses, which we expended for new product development, and we expect to spend another $400,000-$600,000 in this fiscal year to complete the development and testing of our new product line,” said Harvey Grossblatt, Chairman and CEO of Universal.

Universal previewed approximately 25 new products in May at the International Hardware Show in Las Vegas and received very positive feedback from our customers. Initial deliveries of several of these products should begin in the September time frame.

UNIVERSAL SECURITY INSTRUMENTS, INC. is a U.S.-based manufacturer (through its Hong Kong Joint Venture) and distributor of safety and security devices. Founded in 1969, the Company has a 41 year heritage of developing innovative and easy-to-install products, including smoke, fire and carbon monoxide alarms. For more information on Universal Security Instruments, visit our website at http://www.universalsecurity.com/.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the federal securities laws that inherently include certain risks and uncertainties.  Actual results could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors, including, among other items, our and our Hong Kong Joint Venture’s respective ability to maintain operating profitability, currency fluctuations, the impact of current and future laws and governmental regulations affecting us and our Hong Kong Joint Venture and other factors which may be identified from time to time in our Securities and Exchange Commission filings and other public announcements.  We do not undertake and specifically disclaim any obligation to update any forward-looking statements to reflect occurrence of anticipated or unanticipated events or circumstances after the date of such statements.  We will revise our outlook from time to time and frequently will not disclose such revisions publicly.

UNIVERSAL SECURITY INSTRUMENTS, INC.

CONSOLIDATED STATEMENT OF INCOME

(UNAUDITED)

Three Months Ended March 31,

2010

2009

Sales

$6,301,918

$5,928,367

Net income from continuing operations

468,223

36,383

Income per share from continuing operations:

Basic

Diluted

0.20

0.20

0.02

0.02

Gain from discontinued operations

41,767

Gain per share from discontinued operations:

Basic

Diluted

0.02

0.02

Net income

468,223

78,150

Net income per share – basic

0.20

0.03

Net income per share – diluted

0.20

0.03

Weighted average number of common shares outstanding

Basic

Diluted

2,387,887

2,398,927

2,421,755

2,423,323

(AUDITED)

Twelve Months Ended March 31,

2010

2009

Sales

$26,439,118

$26,097,596

Net income from continuing operations

2,268,048

1,442,336

Income per share from continuing operations:

Basic

Diluted

0.95

0.95

0.58

0.58

Gain from discontinued operations

3,423,021

Gain per share from discontinued operations:

Basic

Diluted

1.39

1.38

Net income

2,268,048

4,865,357

Net income per share – basic

0.95

1.97

Net income per share – diluted

0.95

1.96

Weighted average number of common shares outstanding

Basic

Diluted

2,387,887

2,398,300

2,466,983

2,471,807

CONSOLIDATED BALANCE SHEET

ASSETS

March 31,

2010

2009

Cash, cash equivalents and investments

$    6,255,521

$      284,030

Accounts receivable and amount due from factor

4,374,224

5,076,217

Inventory

3,439,906

8,997,231

Prepaid expenses

351,192

255,745

Current assets of discontinued operations

202,565

TOTAL CURRENT ASSETS

14,420,843

14,815,788

INVESTMENT IN HONG KONG JOINT VENTURE

12,153,456

10,550,373

PROPERTY, PLANT AND EQUIPMENT – NET

199,163

251,366

OTHER ASSETS AND DEFERRED TAX ASSET

1,897,292

2,160,151

TOTAL ASSETS

$28,670,754

$27,777,678

LIABILITIES AND SHAREHOLDERS’ EQUITY

Accounts payable and accrued expenses

$  2,162,755

$  2,761,438

Current liabilities of discontinued operations

202,565

Accrued liabilities

279,035

752,452

TOTAL CURRENT LIABILITIES

2,441,790

3,716,455

LONG TERM OBLIGATION

46,459

95,324

SHAREHOLDERS’ EQUITY
Common stock, $.01 par value per share; authorized 20,000,000 shares; issued and outstanding 2,387,887 and 2,408,220 shares at March 31, 2010 and March 31, 2009, respectively

23,879

24,083

Additional paid-in capital

13,135,198

13,186,436

Retained earnings

13,023,428

10,755,380

TOTAL SHAREHOLDERS’ EQUITY

26,182,505

23,965,899

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$28,670,754

$27,777,678

Wednesday, June 23rd, 2010 Uncategorized Comments Off on Universal Security Instruments (UUU) Reports Fourth-Quarter and Year-End Results

IsoRay (ISR) and Hologic (HOLX) Sign Exclusive Worldwide License for Crucial Brain Cancer Treatment Device

RICHLAND, Wash.–(BUSINESS WIRE)–IsoRay, Inc. (Amex: ISRNews) announced today that it has completed a license agreement with Hologic, Inc. (NASDAQ:HOLXNews) for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world’s only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system’s balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

Brain cancer presents unique treatment challenges. Brain tumors are very often difficult to remove completely because of the need to avoid damaging the brain. Further, tumors tend to spread to healthy parts of the brain. Typically, surgeons remove as much as they can of the tumor and then treat the areas surrounding where the tumor was removed with radiation therapy. They sometimes use chemotherapy as well. However, most cancerous brain tumors reoccur shortly following removal, and the cancer tends to return near the site of the original tumor. Brain cancer is one of the fastest growing cancers and recurrence often proves fatal.

The GliaSite system offers a number of advantages in brain cancer treatment. It places a specified high dose of a liquid radiation source in the areas most likely to contain cancer after brain tumor removal and is less likely to damage healthy brain tissue. It helps eliminate the ability for the tumor to reoccur, which in turn impacts patient longevity.

In a related major development, IsoRay is moving forward with the regulatory approval process for its new liquid form of Cesium-131, an exciting advance in brachytherapy for the treatment of brain cancer, that would be delivered using the GliaSite radiation therapy system.

IsoRay CEO Dwight Babcock said physicians have voiced strong support for the GliaSite system and liquid Cesium-131 combination because they recognize the benefits afforded their patients. “In America alone, more than 200,000 men, women, and children are diagnosed with brain cancers every year. The GliaSite therapy system and its use to deliver a liquid radiation source is a versatile, effective treatment for numerous brain cancers,” he said.

Cesium-131 brachytherapy is a patented internal radiation therapy that has several advantages over older radioactive isotopes including faster delivery of a radiation dose that allows less time and opportunity for the cancer cells to repopulate and has a soft energy that minimizes radiation exposure for the operating room and support staff as well as the patient’s family members.

Babcock said this is another step forward in IsoRay’s efforts to advance cancer treatment. “Progress spells hope for patients and the physicians who help them. The GliaSite system represents further achievement as we work toward our goal of expanding brachytherapy solutions throughout the entire body and improving outcomes for cancer patients,” said Babcock.

Previously, approximately 500 GliaSite cases were performed annually at some 40 hospitals worldwide. GliaSite therapy has established reimbursement for both in-patient and out-patient settings.

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.isoray.com&esheet=6337832&lan=en-US&anchor=www.isoray.com&index=7&md5=0882889d4050b715193ea3a142e400ff.

GliaSite is a trademark or registered trademark of Hologic and/or Hologic subsidiaries in the Unites States and/or other countries.

Safe Harbor Statement

Statements in this news release about IsoRay’s future expectations, including: the advantages of our Proxcelan Cesium-131 seed, the advantages of the Gliasite delivery system, whether a liquid form of Cesium-131 will be developed that receives regulatory approval and can be used successfully with the Gliasite delivery system, whether IsoRay will be able to expand its base beyond prostate cancer, whether IsoRay’s Cesium-131 seed will be used to treat additional cancers and malignant disease, whether the use of Cesium-131 to treat brain or other cancers will be successful in the initial and any future implants, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, whether initial implants of Cesium-131 to treat brain or other cancers result in favorable patient outcomes, whether resources are available as needed to develop a liquid form of Cesium-131 and whether such liquid form receives and maintains all required regulatory approvals, whether any liquid form of Cesium-131 is able to be used successfully with the Gliasite delivery system, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer whether with the Gliasite delivery system or in another delivery system, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

Wednesday, June 23rd, 2010 Uncategorized Comments Off on IsoRay (ISR) and Hologic (HOLX) Sign Exclusive Worldwide License for Crucial Brain Cancer Treatment Device

Hawk Corporation (HWK) Raises Full Year 2010 Guidance

CLEVELAND, OH–(Marketwire – 06/23/10) – Hawk Corporation (AMEX:HWKNews) announced today that it is raising its guidance for 2010 net sales and operating income based on the expected strength of its second quarter results and an improved outlook for the second half of the year.

The outlook for the construction and mining and heavy truck markets continues to improve, and the strength in these categories is influencing the Company’s revised guidance. Hawk is increasing its guidance for 2010 full year net sales to a range of between $225.0 million to $232.0 million from its previous guidance range of between $200.0 million to $210.0 million. This new guidance represents an increase of between 30.5% and 34.6% over 2009 revenues of $172.4 million.

Based on the impact of these higher sales volumes, Hawk is also increasing its guidance for 2010 full year operating income to a range of between $32.0 million and $35.0 million from its previous guidance of between $23.0 million and $25.0 million. This new guidance range represents an increase of between 91.6% and 109.6% over 2009 operating income of $16.7 million.

Ronald E. Weinberg, Hawk’s Chairman and CEO, said, “The volatility that persisted in the global economy in 2009 is giving way to more certainty that our first quarter results are sustainable. We believe that Hawk is benefitting from the improving global economy, and we see specific strength in our construction and mining and heavy truck end markets. In addition, because we continued to focus on key initiatives throughout the downturn, we have emerged strengthened and find that our business strategies are beginning to lead to increased revenue.”

The Company is revising its guidance for depreciation and amortization expense to approximately $8.0 million from its previous guidance of approximately $8.5 million and capital spending for 2010 to a range of between $7.0 million and $9.0 million from its previous guidance of between $8.0 million and $10.0 million. Additionally, Hawk is lowering its effective worldwide tax rate guidance to approximately 35.0% from its previous guidance of approximately 36.0%.

Management has not scheduled a conference call in conjunction with this revised guidance. The second quarter ends shortly and additional information will be available when the Company reports its financial results in August.

The Company
Hawk Corporation is a leading supplier of friction materials for brakes, clutches and transmissions used in airplanes, trucks, construction and mining equipment, farm equipment, recreational and performance automotive vehicles. The Company also operates a fuel cell components business. Headquartered in Cleveland, Ohio, Hawk has approximately 1,200 employees at 12 manufacturing, research and development, sourcing, sales and administrative sites in 6 countries.

Forward-Looking Statements
This press release includes forward-looking statements concerning sales, operating earnings, depreciation and amortization expense, capital expenditures and effective tax rates. These forward-looking statements are based upon management’s expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company and which could cause actual results to differ materially from such statements. These risks and uncertainties include, but are not limited to the Company’s ability to execute its business plan to meet its sales, operating income, cash flow and capital expenditure guidance and other risks detailed in Hawk’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and other periodic filings.

Actual results and events may differ significantly from those projected in the forward-looking statements. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Hawk Corporation is online at: http://www.hawkcorp.com/

Wednesday, June 23rd, 2010 Uncategorized Comments Off on Hawk Corporation (HWK) Raises Full Year 2010 Guidance

Bsquare (BSQR) Renews OEM Distribution Agreement With Microsoft for 12th Year

BELLEVUE, WA–(Marketwire – 06/23/10) – BSQUARE Corporation (NASDAQ:BSQRNews), the leading software solutions provider to the global embedded device community, has renewed its OEM distribution agreement with Microsoft Corporation under which Bsquare sells Microsoft’s complete line of embedded software products to OEMs in North America. The new agreement is effective for the period July 1, 2010 to June 30, 2011.

This agreement allows Bsquare to assist OEMs to license Microsoft embedded software products including Windows Embedded CE, Windows Embedded Standard, XP Pro for Embedded Systems and Windows Embedded Server. Additionally, Bsquare is a global distributor for Windows Mobile licensing.

According to analyst firm VDC Research, an estimated 2.3 million enterprise handheld devices were shipped in 2009 and this number is projected to exceed 4.3 million by 2014.

“It’s an exciting time to be a part of the embedded device market and we are pleased to continue building on the successful relationship that Microsoft has with Bsquare,” said Microsoft’s Doug Follett, Director of OED for the Americas and EMEA. “Device makers will benefit from Microsoft’s investments in the enterprise handheld device market and new products based on the Windows 7 platform. Bsquare’s engineering services and products bring critical value to OEMs seeking hardware or software expertise to bring their devices to market faster.”

“The release of Windows Embedded Standard 7 and Microsoft’s commitment to the enterprise handheld device market will continue to drive success for Bsquare in the coming quarters,” said Scott Caldwell, Bsquare’s Director of Licensing Sales. “Windows Embedded Standard 7 fundamentally changes how embedded devices are developed. On this platform, embedded devices can be created easily and rapidly, allowing a new class of OEMs to easily enter the embedded market.”

As the only North American distributor that is nearly 100 percent focused on Windows Embedded products, Bsquare offers personalized account management and highly responsive technical support. In addition Bsquare offers value added products, engineering services, automated testing, technical support and training to enable device OEMs to move from prototyping and development to testing and production faster, with higher quality devices.

About Bsquare
Bsquare is an industry leader with a proven track record in providing production-ready software products and engineering services to the smart device market. Since 1994, Bsquare has provided device manufacturers with software solutions for personal navigation devices, point-of-sale terminals, handheld data terminals, smart phones and many other device categories allowing them to get to market more quickly and cost effectively.

For more information, visit http://www.bsquare.com/services/Automotive.asp.

Wednesday, June 23rd, 2010 Uncategorized Comments Off on Bsquare (BSQR) Renews OEM Distribution Agreement With Microsoft for 12th Year

Lightbridge (LTBR) Invents New Transformational Nuclear Fuel Technology

MCLEAN, Va., June 23, 2010 (GLOBE NEWSWIRE) — Lightbridge Corporation (Nasdaq:LTBR), the leading developer of non-proliferative nuclear fuel technology and provider of comprehensive advisory services for civil nuclear energy programs, today announced a major technological breakthrough that has the potential to transform the nuclear power industry.  Lightbridge’s new fuel technology based on a proprietary all-metal fuel assembly design could reduce both initial capital costs per megawatt and annual operating costs per kilowatt-hour of nuclear power, making it more competitive with other forms of electricity generation while contributing to a significant reduction of CO2 emissions.

It is expected that Lightbridge’s all-metal fuel technology could be applied to currently operating or new light water reactors as well as small modular reactors which provide the same benefits as in larger commercial nuclear power plants.  It is also highly synergistic with fast reactor fuel designs.

One of the key benefits of the Lightbridge-designed all-metal fuel technology is a potential 30% increase in power output per reactor compared to reactors using standard oxide nuclear fuel.  This could translate into additional revenue for a 1,600-MWe light water reactor of up to $250 million or more per year, or nearly $16 billion over a 60-year expected lifetime of such reactors.  This increased power output is expected to lower operating costs on a per kilowatt-hour basis and strengthen the economics of nuclear power versus other forms of power generation.  In addition, currently operating light water reactors could also take advantage of this power uprate by switching to Lightbridge’s all-metal fuel design.

The Lightbridge-designed all-metal fuel design would provide enhanced proliferation resistance and result in up to 23% less volume of used fuel per kilowatt-hour of electricity generated and is expected to have improved fuel operation compared to standard oxide fuel.

“When it comes to meeting the ever increasing global demand for power generation, innovation will be the key to a sustainable and safe solution for industry and governments worldwide,” said Seth Grae, CEO, Lightbridge.  “Our breakthrough all-metal fuel technology builds upon over a decade of research and development effort that has been underway on our seed-and-blanket fuel assembly design.  This transformational fuel technology also helps advance our seed-and-blanket fuel assembly designs due to the synergies between the seed fuel rods and the fuel rods used in the all-metal fuel assembly design.  We expect that our all-metal nuclear fuel technology will provide significant economic incentives to nuclear utilities that make it economically attractive to adopt this advanced fuel product.”

As was previously announced, on June 10, 2010, Idaho National Laboratory approved a Texas A&M University-led joint proposal with Lightbridge for irradiation testing of this kind of metallic fuel in the Advanced Test Reactor.  The fuel demonstration in a test reactor environment is a key stepping stone to demonstration and deployment of this fuel in commercial Western-type light water reactors.

Sam Vaidyanathan, a member of Lightbridge’s Technical Advisory Board with more than 30 years of experience with the development, testing, and engineering of nuclear fuels, materials, and core components at major nuclear companies, added, “Simply stated this development is a very significant one for the nuclear power industry.  For those of us who have been in this business for the last few decades, this development without a doubt is transformational.  The tangible benefits are clear, measurable, and will likely have a substantive impact on the future of the nuclear power industry.  We’re very pleased and excited about this technological breakthrough.”

Over the past decade, Lightbridge has completed significant development and testing relating to this all-metal fuel technology.  In particular, Lightbridge has evaluated key operating parameters under various operating conditions. Some of the key parameters that were evaluated include: melting point, fission gas retention, surface heat flux, fuel swelling, moderator-to-fuel ratio, cladding corrosion, and others.  The results of the evaluation performed to-date indicate that the fuel performance would meet applicable criteria for safe operation.

About Lightbridge Corporation

Lightbridge is a U.S. nuclear energy company based in McLean, VA. with operations in Abu Dhabi, Moscow and London. The Company develops non-proliferative nuclear fuel technology and provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence.  Lightbridge’s breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way towards a sustainable energy future.  Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations.  It leverages those broad and integrated capabilities by offering their services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.

The Lightbridge Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6636

Safe Harbor Statement

This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements.  Forward-looking statements can be identified by the use of forward-looking terminology such as ‘will,’ ‘believes,’ ‘expects’ or similar expressions.  Such information is based upon expectations of our management that were reasonable when made but may prove to be incorrect.  All of such assumptions are inherently subject to uncertainties and contingencies beyond our control and based upon premises with respect to future business decisions, which are subject to change.  We do not undertake to update the forward-looking statements contained in this press release.  For a description of the risks and uncertainties that may cause actual results to differ from the forward-looking statements contained in this press release, see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (‘SEC’), and our subsequent SEC filings.  Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system at http://www.sec.gov .

Wednesday, June 23rd, 2010 Uncategorized Comments Off on Lightbridge (LTBR) Invents New Transformational Nuclear Fuel Technology

Inovio Pharmaceuticals’ (INO) Optimized DNA Vaccine Demonstrates Significant Advantages

BLUE BELL, Pa.–(BUSINESS WIRE)–Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled “Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques.” The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses. In this head-to-head comparison with an adenovirus serotype 5 (Ad5) vaccine considered to be the most immunogenic among viral vectors, Inovio’s optimized SynCon™ DNA vaccine delivered using its proprietary electroporation technology demonstrated numerous advantages in both magnitude and breadth of immune responses produced in non-human primates.

Compared to Ad5, the SynCon™ DNA vaccine resulted in:

  • Significantly stronger antigen-specific cellular immune responses, in particular CD8+ T cells. T cells are considered instrumental in clearing cancerous or infected cells from the body. Such responses are therefore imperative to achieving sufficient potency in new vaccines against cancers and chronic infectious diseases such as HIV and hepatitis C virus. Importantly, Ad5 immunizations failed to boost immune responses following the first immunization, whereas immune responses from DNA vaccination were continually boosted even after four immunizations.
  • Increased breadth of T cell-based immune responses. CD4+ and CD8+ T cell immune responses produced with DNA vaccination were broader and produced multiple immune molecules called cytokines (IFNγ, IL-2, TNF-α, and CD107a). Broad immune responses are considered an important potential marker for vaccine efficacy.
  • Immune responses that were long-lasting and maintained at high levels.

Dr. David Weiner, Professor, Department of Pathology & Laboratory Medicine and Chair, Gene Therapy and Vaccines Program at the University of Pennsylvania, and the lead author of the paper, commented: “While Ad5 is particularly potent after a single immunization, its apparent susceptibility to pre-existing immune responses is a concerning limitation. We were pleased to see the superior magnitude and quality of immune responses generated by Inovio’s SIV DNA vaccine delivered using electroporation. Moreover, the ability of this technology to continuously boost immune responses after multiple immunizations is an accomplishment that bodes well for the application of this vaccine platform for diseases requiring strong T cell responses, such as HIV, hepatitis C virus, and cancers.” Dr. Weiner is also chairman of Inovio’s scientific advisory board.

Dr. J. Joseph Kim, Inovio’s CEO and also a co-author of the paper, said: “This study highlights that Inovio’s DNA vaccine platform has achieved levels of immune responses previously not achievable and is playing an important role in further advancing this important new generation of vaccines. These results have more recently been supported by the human data reported from our HPV clinical trial, which demonstrated unprecedented levels of cellular and humoral (antibody) responses.”

Inovio’s PENNVAX™-B HIV vaccine is currently being tested in two separate Phase I clinical studies (preventive and therapeutic settings). Inovio is developing two additional globally targeted HIV vaccine candidates, PENNVAX™-G and PENNVAX™-GP, in a collaboration with the US Military HIV Vaccine Research Program and via a multi-year $23.5 million NIAID HIV vaccine development contract, respectively.

SynCon™ DNA Vaccine vs. Ad5 Study Details

Previous studies demonstrated that the most potent recombinant vector system for induction of cellular immune (T cell) responses in macaques and humans is adenovirus serotype 5 (Ad5). However, an Ad5 based vaccine tested in one of the largest HIV clinical trials to date, the Step Study, was halted due to a lack of efficacy. New vaccine approaches must produce more potent immune responses to have a better prospect of succeeding in the clinic. This study compared Merck’s Ad5 SIV vaccine (SIVmac239 gag, nef, and pol immunogens) and Inovio’s optimized electroporation-delivered SIV DNA vaccine (consensus macSIV gag, env, and pol immunogens) in macaques. SIV, the HIV equivalent in non-human primates, is considered an important pre-clinical model for HIV vaccine development. The study compared previously optimized doses and immunization conditions for the two SIV vaccines: animals receiving the Ad5 vaccine were immunized three times; DNA-vaccinated animals were immunized up to four times. The researchers assessed magnitude and quality of the cellular responses induced by each approach. This study was funded in part by a grant from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID).

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. The company’s SynCon™ “universal” vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. When delivered with Inovio’s proprietary electroporation delivery devices the vaccines have been shown to be safe and to generate significant immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic), avian flu, and HIV vaccines (both preventive and therapeutic). Inovio is developing its universal influenza vaccines in collaboration with scientists from the University of Pennsylvania and National Microbiology Laboratory of the Public Health Agency of Canada. Other partners and collaborators include Merck, ChronTech, University of Southampton, National Cancer Institute, HIV Vaccines Trial Network, and Malaria Vaccine Initiative/PATH. More information is available at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.inovio.com&esheet=6336027&lan=en-US&anchor=www.inovio.com&index=1&md5=0007ce70c2f78d805e01e20d1da08040.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the three months ended March 31, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Tuesday, June 22nd, 2010 Uncategorized Comments Off on Inovio Pharmaceuticals’ (INO) Optimized DNA Vaccine Demonstrates Significant Advantages

Stream Global Services (SGS) Renews Agreement With ITIDA for Egyptian Workforce Development

BOSTON, June 22 /PRNewswire-FirstCall/ — Stream Global Services, Inc., (NYSE Amex: SGS), a premium business process outsource (BPO) service provider specializing in customer relationship management for Fortune 1000 companies, today announced that it has renewed its agreement with the Egyptian Information Technology Development Agency (ITIDA) to employ and train Egyptian employees in its Cairo facility.  ITIDA, as part of its initiative to empower, grow and develop Egypt‘s information and communications technology industry, will continue to subsidize certain employee training costs for Stream.  Stream expects its staff in Cairo to grow from 1000 employees to close to 4000 employees over the next three years.

Stream’s Chairman and CEO, Scott Murray, signed the agreement today with Dr. Hazem Youssef Abdelazim, CEO, ITIDA, during the American Chamber of Commerce in Egypt event, taking place in Washington, DC. The agreement was witnessed by the Minister of Communications and Information Technology, His Excellency, Dr. Tarek Kamel. In addition to the signing, Mr. Murray will also participate in a panel discussion with other leading global companies regarding its recent business success in Egypt.

“Since the opening of our Cairo service center just over a year ago, Stream has seen tremendous growth and success in the region,” said Murray.  “The excellent language skills, labor pool scalability and exceptional government support has enabled us to provide unparalled service programs for our clients.  We are thrilled to continue our work with the ITIDA to ensure that we quickly and effectively ramp up training and support efforts in Cairo for these clients.”

According to a recent Ovum research article, Egypt has a significant role to play in the delivery of customer-facing services to Western end-users.  According to Ovum analyst and author, Peter Ryan, “Stream’s decision to move into Egypt for contact center delivery highlights the significant value this market has to offer.”

Commenting on the agreement, ITIDA CEO, Dr. Hazem Youssef Abdelazim said, “We are pleased to continue our work with Stream to further develop the technology talent base of Egypt.  We look forward to our continued partnership over the coming years to ensure Stream’s clients reap the benefits of Egypt‘s advanced technology infrastructure and highly educated workforce. More importantly, Stream’s success with ITIDA support, proves that Egypt has positioned itself as next large scale location for global BPO and Call Center requirements.”

Contact Information:

Sally Comollo

Director of Marketing Communications

sally.comollo@stream.com

781-304-1847

About Stream Global Services

Stream Global Services is a premium business process outsource (BPO) service provider specializing in customer relationship management including sales, customer care and technical support for Fortune 1000 companies.  Stream is a trusted partner to some of the world’s leading technology, computing, telecommunications, retail, entertainment/media, and financial services companies.  Our service programs are delivered through a set of standardized best practices and sophisticated technologies by a highly skilled workforce of approximately 30,000 employees based out of 50 solution centers in 22 countries supporting more than 35 languages.  Stream continues to expand its global presence and service offerings to increase revenue, improve operational efficiencies and drive brand loyalty for its clients. To learn more about the company and its complete service offering, please visit http://www.stream.com/.

About IDITA

The Information Technology Industry Development Agency (ITIDA) is a governmental entity affiliated to Egypt‘s Ministry of Communications and Information Technology.  It is responsible for growing and developing Egypt‘s position as a leading global outsourcing location by attracting foreign direct investment to the industry and maximizing the exports of IT services and applications.

Located in the heart of the modern business environment at Smart Village, the six hundred acre technology and business park on the outskirts of Cairo, ITIDA is a self-sustainable entity that drives the IT industry in Egypt and raises awareness among the Egyptian people of the benefits and use of ICT to advance socio-economic welfare of the whole community. To learn more about ITIDA and its activities, please visit http://www.itida.gov.eg/

Tuesday, June 22nd, 2010 Uncategorized Comments Off on Stream Global Services (SGS) Renews Agreement With ITIDA for Egyptian Workforce Development

VirnetX (VHC) Victorious in Patent Review

SCOTTS VALLEY, Calif., June 22 /PRNewswire-FirstCall/ — VirnetX Holding Corporation (NYSE Amex: VHC), an Internet security software and technology company, announced today that on June 16, 2010, the United States Patent and Trademark Office (USPTO) confirmed all claims of VirnetX’s U.S. Patent No. 6,502,135 and U.S. Patent No. 7,188,180 are patentable and valid.

U.S. Patent No. 6,502,135, entitled “Agile Network Protocol for Secure Communications with Assured System Availability” and U.S. Patent No. 7,188,180, entitled “Method for Establishing Secure Communication Link Between Computers of Virtual Private Network,” were determined to have been infringed by Microsoft at a jury trial in a patent infringement suit that was settled by VirnetX and Microsoft for $200 million on May 17, 2010.

“The validation of these two key patents and all the claims associated with each by the USPTO further validates the importance and strength of our patent portfolio,” said Kendall Larsen, VirnetX President and CEO.  “Furthermore, this confirms that VirnetX has key patents related to one of the most ubiquitous and important security technologies, Virtual Private Networks.”

About VirnetX

VirnetX Holding Corporation, an Internet security software and technology company, is engaged in commercializing its patent portfolio,  by developing a licensing program as well as developing software products designed to create a secure environment for real-time communication applications such as instant messaging,  VoIP, smart phones, eReaders and video conferencing. The Company’s patent portfolio includes over 48 U.S. and international patents and pending applications that were recently declared as essential for 4G security specifications and provide the foundation for the Company’s unique GABRIEL Connection Technology. For more information, please visit http://www.virnetx.com/.

Tuesday, June 22nd, 2010 Uncategorized Comments Off on VirnetX (VHC) Victorious in Patent Review

Iridium (IRDM) Expands Reach With South African License GlobeNewswire (Tue 7:00AM EDT)

MCLEAN, Va. and JOHANNESBURG, South Africa, June 22, 2010 (GLOBE NEWSWIRE) — Iridium Communications Inc. (Nasdaq:IRDMNews) announces the establishment of “Iridium South Africa,” under which Iridium has licenses to operate, provide and sell mobile satellite services (MSS) in the country. The authorization was provided by the Independent Communications Authority of South Africa (ICASA), the regulator for the South African communications and broadcasting services. This authorization enables Iridium partners the ability to better address the growing government and commercial enterprise market demand with Iridium products, services and applications in the country.

The Iridium low-Earth orbiting (LEO) satellite constellation provides mobile voice and data communications over the entire planet, offering service where no other means of communication exists. As a result of the new communications licenses, the government, business and consumer sectors in South Africa now have greater access to the world’s only truly global MSS.

“Iridium has grown its commercial service revenues between 2006 and 2009 at a compound annual growth rate (CAGR) of more than 27 percent, primarily through the introduction of new products and services, attraction of new distribution partners, and expansion of its geographic sales reach,” said Matt Desch, CEO, Iridium. “This announcement continues to demonstrate the demand for Iridium’s MSS around the globe. South Africa is an important and growing market that requires Iridium’s broad, reliable, dependable, mobile communications services.”

Iridium anticipates its MSS can be utilized by the South African government to provide backup communications in urban and rural areas, and in emergency situations, as is the case in many regions of the world. Iridium’s global low-latency, two-way machine-to-machine (M2M) communications are ideal for markets such as transportation, logistics, security, oil and gas, and mining where there are requirements to deliver continuous, intelligent communications on valuable assets in real time. In addition, there is significant demand from global companies looking to expand their operations in the country.

Iridium voice and data services are particularly ideal for South Africa because of its coastal access to the South Atlantic Ocean and Indian Ocean, as well as its large rural land mass and significant mining operations. The country’s established and emerging industries, growing infrastructure and adventure tourist industry also make Iridium an essential service in South Africa.

“A satellite communications service such as Iridium’s, with service covering the entire globe, as well as all corners of our country, including her shores and areas that may never be served otherwise by current service providers, is an enormous development for South Africa,” said Dr. John K. Nkadimeng, patron of the John Kgoana Nkadimeng Foundation, and one of the champions of the liberation struggle for freedom in South Africa. Nkadimeng, along with Nelson R. Mandela, is one of the original 1956 Treason Trial anti-apartheid defendants.

In addition to the existing partners with export operations in South Africa, Iridium anticipates opportunities for its more than 200 global distribution partners to form new partnerships to deliver a range of innovative voice and data applications that will connect the South African market to the global reach of the Iridium network.

Demand for truly global MSS has helped fuel the company’s international expansion as well as plans to build its next-generation satellite constellation, Iridium NEXT. Iridium continues to pursue licenses in other significant geographical markets, such as Russia and China, which represent the opportunity for further expansion of the company’s products and services.

About Iridium Communications Inc.

Iridium Communications Inc. (http://www.globenewswire.com/newsroom/ctr?d=194794&l=9&a=www.iridium.com&u=http%3A%2F%2Fwww.iridium.com) is the only mobile satellite service (MSS) company offering coverage over the entire globe. The Iridium constellation of low-earth orbiting (LEO) cross-linked satellites provides critical voice and data services for areas not served by terrestrial communication networks. Iridium serves commercial markets through a worldwide network of distributors, and provides services to the U.S. Department of Defense and other U.S. and international government agencies. The company’s customers represent a broad spectrum of industry, including maritime, aeronautical, government/defense, public safety, utilities, oil/gas, mining, forestry, heavy equipment and transportation. Iridium has launched a major development program for its next-generation satellite constellation, Iridium NEXT. The company is headquartered in McLean, Va., USA and trades on the NASDAQ Global Market under the ticker symbols IRDM (common stock), IRDMW ($7.00 warrants), IRDMZ ($11.50 warrants) and IRDMU (units).

Forward-Looking Statements

Statements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding expected usage of Iridium’s mobile satellite services (MSS). Other forward-looking statements can be identified by the words “anticipates,” “may,” “can,” “believes,” “expects,” “projects,” “intends,” “likely,” “will,” “to be” and other expressions that are predictions of or indicate future events, trends or prospects. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Iridium to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties regarding overall levels of demand for MSS, and the company’s ability to maintain the health, capacity and content of its satellite constellation, as well as general industry and economic conditions, and competitive, legal, governmental and technological factors. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission on March 16, 2010. There is no assurance that Iridium’s expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium’s underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected.

Iridium’s forward-looking statements speak only as of the date of this press release and Iridium undertakes no obligation to update forward-looking statements.

Tuesday, June 22nd, 2010 Uncategorized Comments Off on Iridium (IRDM) Expands Reach With South African License GlobeNewswire (Tue 7:00AM EDT)

Merck (MRK) and Codexis (CDXS) Honored with Presidential Green Chemistry Challenge Award

Jun. 21, 2010 (Business Wire) — Merck and Codexis, Inc. (NASDAQ:CDXS) today announced that they have jointly been awarded the annual Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) for the development of a novel biocatalytic method for the synthesis of sitagliptin. In addition, a paper co-authored by Merck and Codexis scientists and published online June 17 in the peer-reviewed journal Science, details how an enzyme was systematically customized using Codexis technology to perform the key chemical step in the sitagliptin synthesis process. This process showed improved efficiency and significantly decreased chemical waste byproducts.

“Merck has a longstanding commitment to environmental sustainability,” said Richard Tillyer, Ph.D, head of Drug Discovery and Preclinical Sciences, Merck Research Laboratories. “This award and the recent publication underscore the strength of the innovative science and the productive collaboration with our colleagues at Codexis.”

The publication in Science outlines how Merck and Codexis collaborated to create a custom enzyme, or biocatalyst, that can allow for commercial-scale manufacturing of sitagliptin. No natural enzyme able to produce this compound was found. Enzymes are biodegradable, renewable and are generally believed to provide a more sustainable means of chemical synthesis than many currently employed methods used for the manufacture of pharmaceuticals. Evidence suggests that the new process may offer a 10-13 percent overall increase in yield of sitagliptin over the current process and a significant reduction in waste byproducts.

“Codexis is honored to receive one of the U.S. government’s highest awards for environmental protection with Merck,” said Alan Shaw, Ph.D., Codexis President and CEO. “Our proven technology platform is in use around the world, enabling creation of cleaner, more efficient pharmaceutical manufacturing processes. We are committed, with our colleagues at Merck, to leveraging the power of green chemistry for a sustainable environment.”

About Presidential Green Chemistry Challenge Awards Program

The Presidential Green Chemistry Challenge Awards are presented annually by the Environmental Protection Agency to recognize new technologies that help prevent pollution by reducing or eliminating hazardous waste in industrial production. It provides recognition of outstanding chemical technologies that incorporate the principles of green chemistry into chemical design, manufacture, and use, and that have been or can be utilized by industry in achieving their pollution prevention goals. The award was launched in 1995 in partnership with the chemical industry, the American Chemical Society, the National Academies and other stakeholders. Both Merck and Codexis won awards individually in 2006.

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck. Be well. For more information, visit www.merck.com.

About Codexis

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. For more information, visit www.codexis.com.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2009 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Codexis Forward-Looking Statement

This press release contains forward-looking statements relating to the benefits of the novel biocatalytic method for the synthesis of sitagliptin and the future environmental benefits of green chemistry as discussed in this press release. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis’ Quarterly Report on Form 10-Q dated May 28, 2010 including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6333559&lang=en

Monday, June 21st, 2010 Uncategorized Comments Off on Merck (MRK) and Codexis (CDXS) Honored with Presidential Green Chemistry Challenge Award
Top Small Cap Market News